person · Reporting owner

Casdin Eli

Disclosed activity across 14 companies

Tapewire entity: 36006
SEC CIK: 0001534264

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Absci CorpABSI · Entity 4685	Director	June 08, 2022	June 10, 2022
Century Therapeutics, Inc.IPSC · Entity 5739	Director	June 09, 2022	June 10, 2022
EXACT SCIENCES CORPEXAS · Entity 56619	Director	July 23, 2020	July 24, 2020
GeneDx Holdings Corp.WGS · Entity 1634	Director · 10% owner	June 18, 2026	June 23, 2026
STANDARD BIOTOOLS INC.LAB · Entity 6116	Director · 10% owner	June 18, 2026	June 23, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Absci Corp

Report date June 08, 2022 · Filed June 10, 2022

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.39 · Expires 2032-06-07	Direct	28,700	Reported balance After 2022-06-08 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2022-06-08 · Grant · Acquired 28,700 · Balance 28,700 F1: The shares subject to this option vest and become exercisable in full on the earlier of (i) the first anniversary of the date of grant and (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer through such date.

Filing footnotes · ownership attribution and instrument terms

F1: The shares subject to this option vest and become exercisable in full on the earlier of (i) the first anniversary of the date of grant and (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer through such date.

Century Therapeutics, Inc.

Report date June 09, 2022 · Filed June 10, 2022

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.56 · Expires 2032-06-09	Direct	19,872	Reported balance After 2022-06-09 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2022-06-09 · Grant · Acquired 19,872 · Balance 19,872 F1: The option vests on the earlier of (a) June 9, 2023, or (b) the next annual meeting of stockholders, in each case subject to the Reporting Person's continued service through the applicable vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The option vests on the earlier of (a) June 9, 2023, or (b) the next annual meeting of stockholders, in each case subject to the Reporting Person's continued service through the applicable vesting date.

EXACT SCIENCES CORP

Report date July 23, 2020 · Filed July 24, 2020

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	8,820	Reported balance After 2020-07-23 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2020-07-23 · Grant · Acquired 2,558 · Balance 8,820 F1: These shares of restricted stock were issued pursuant to the Company's non-employee director compensation policy.
Common StockSEC Table I · non-derivative	IndirectBy child	225	Reported balance Holding disclosure · report date 2020-07-23 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 225
Common StockSEC Table I · non-derivative	IndirectBy child	225	Reported balance Holding disclosure · report date 2020-07-23 · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · Balance 225

Filing footnotes · ownership attribution and instrument terms

F1: These shares of restricted stock were issued pursuant to the Company's non-employee director compensation policy.

GeneDx Holdings Corp.

Report date June 18, 2026 · Filed June 23, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class A Common StockSEC Table I · non-derivative	Direct	24,093	Reported balance After 2026-06-18 transaction · row 1 1 source row Row 1 · 2026-06-18 · Exercise / conversion · Acquired 3,576 · Balance 24,093 F1: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration.
Restricted Stock UnitSEC Table II · derivative / convertible security	Direct	4,248	Reported balance After 2026-06-18 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2026-06-18 · Grant · Acquired 4,248 · Balance 4,248 F1: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. F5: The entire award shall vest on the earlier of the (i) date of the 2027 annual meeting of the Issuer's stockholders, or (ii) first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through the vesting date. These RSUs do not have an expiration date; they either vest or are cancelled prior to the vesting date.
Restricted Stock UnitSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2026-06-18 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2026-06-18 · Exercise / conversion · Disposed 3,576 · Balance 0 F1: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. F6: The entire award vested or vests on the earlier of the: (i) date of the 2026 annual meeting of the Issuer's stockholders, or (ii) first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through the vesting date. These RSUs do not have an expiration date; they either vest or are cancelled prior to the vesting date.
Class A Common StockSEC Table I · non-derivative	IndirectBy Casdin Partners Master Fund, LP	3,707,164	Reported balance Holding disclosure · report date 2026-06-18 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 3,707,164 F2: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to the Master Fund ("Casdin"), (ii) Casdin Partners GP, LLC, the general partner of the Master Fund (the "GP"), and (iii) the Reporting Person, who is the managing member of Casdin and the GP.
Class A Common StockSEC Table I · non-derivative	IndirectBy Casdin Partners GP, LLC	19,247	Reported balance Holding disclosure · report date 2026-06-18 · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · Balance 19,247 F3: The securities are owned directly by the GP and may be deemed to be indirectly beneficially owned by the Reporting Person, who is the managing member of the GP.
Class A Common StockSEC Table I · non-derivative	IndirectBy CMLS Holdings LLC	333,144	Reported balance Holding disclosure · report date 2026-06-18 · row 4 Holding and transaction disclosures are not merged. 1 source row Row 4 · Balance 333,144 F4: The securities are owned directly by CMLS Holdings LLC ("CMLS Holdings"). The Board of Managers of CMLS Holdings includes the Reporting Person, who, as a member of the Board of Managers of CMLS Holdings, shares voting and investment discretion with respect to securities held by CMLS Holdings.

Filing footnotes · ownership attribution and instrument terms

F1: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration.

F2: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to the Master Fund ("Casdin"), (ii) Casdin Partners GP, LLC, the general partner of the Master Fund (the "GP"), and (iii) the Reporting Person, who is the managing member of Casdin and the GP.

F3: The securities are owned directly by the GP and may be deemed to be indirectly beneficially owned by the Reporting Person, who is the managing member of the GP.

F4: The securities are owned directly by CMLS Holdings LLC ("CMLS Holdings"). The Board of Managers of CMLS Holdings includes the Reporting Person, who, as a member of the Board of Managers of CMLS Holdings, shares voting and investment discretion with respect to securities held by CMLS Holdings.

F5: The entire award shall vest on the earlier of the (i) date of the 2027 annual meeting of the Issuer's stockholders, or (ii) first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through the vesting date. These RSUs do not have an expiration date; they either vest or are cancelled prior to the vesting date.

F6: The entire award vested or vests on the earlier of the: (i) date of the 2026 annual meeting of the Issuer's stockholders, or (ii) first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through the vesting date. These RSUs do not have an expiration date; they either vest or are cancelled prior to the vesting date.

STANDARD BIOTOOLS INC.

Report date June 18, 2026 · Filed June 23, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	3,053,169	Reported balance After 2026-06-18 transaction · row 1 1 source row Row 1 · 2026-06-18 · Grant · Acquired 99,116 · Balance 3,053,169 F1: Represents Restricted Stock Units ("RSUs") that vest in full on the earlier to occur of June 18, 2027 and one day prior to the date of the Company's next annual meeting of stockholders, subject to the Reporting Person's continued service through the applicable vesting date. Each RSU represents the right to receive one share of common stock upon vesting.
Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.83 · Expires 2036-06-18	Direct	175,923	Reported balance After 2026-06-18 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2026-06-18 · Grant · Acquired 175,923 · Balance 175,923 F5: The Option becomes exercisable in twelve equal monthly installments beginning on July 18, 2026, subject to the Reporting Person's continued service through the applicable vesting date.
Common StockSEC Table I · non-derivative	IndirectCasdin Private Growth Equity Fund II, L.P.	13,939,637	Reported balance Holding disclosure · report date 2026-06-18 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 13,939,637 F2: The securities are owned directly by Casdin Private Growth Equity Fund II, L.P. (the "Equity Fund II") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin"), the investment adviser to the Equity Fund II, and (ii) Eli Casdin, the managing member of Casdin.
Common StockSEC Table I · non-derivative	IndirectBy Casdin Private Growth Equity Fund, L.P.	2,744,219	Reported balance Holding disclosure · report date 2026-06-18 · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · Balance 2,744,219 F3: The securities are owned directly by Casdin Private Growth Equity Fund, L.P. (the "Equity Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin, the investment adviser to the Equity Fund, and (ii) Eli Casdin, the managing member of Casdin.
Common StockSEC Table I · non-derivative	IndirectCasdin Partners Master Fund, L.P.	72,100,000	Reported balance Holding disclosure · report date 2026-06-18 · row 4 Holding and transaction disclosures are not merged. 1 source row Row 4 · Balance 72,100,000 F4: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin, the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC, the general partner of the Master Fund (the "GP"), and (iii) Eli Casdin, the managing member of Casdin and the GP.

Filing footnotes · ownership attribution and instrument terms

F1: Represents Restricted Stock Units ("RSUs") that vest in full on the earlier to occur of June 18, 2027 and one day prior to the date of the Company's next annual meeting of stockholders, subject to the Reporting Person's continued service through the applicable vesting date. Each RSU represents the right to receive one share of common stock upon vesting.

F2: The securities are owned directly by Casdin Private Growth Equity Fund II, L.P. (the "Equity Fund II") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin"), the investment adviser to the Equity Fund II, and (ii) Eli Casdin, the managing member of Casdin.

F3: The securities are owned directly by Casdin Private Growth Equity Fund, L.P. (the "Equity Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin, the investment adviser to the Equity Fund, and (ii) Eli Casdin, the managing member of Casdin.

F4: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin, the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC, the general partner of the Master Fund (the "GP"), and (iii) Eli Casdin, the managing member of Casdin and the GP.

F5: The Option becomes exercisable in twelve equal monthly installments beginning on July 18, 2026, subject to the Reporting Person's continued service through the applicable vesting date.

Past disclosures · reporting ended (9)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

2seventy bio, Inc.

Report date May 13, 2025 · Filed May 15, 2025

Jointly reported with Casdin Capital, LLC, Casdin Partners Master Fund, L.P., Casdin Partners GP, LLC

Section 16 reporting ended · disclosed 2025-05-15. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common Stock, par value $0.0001 per shareSEC Table I · non-derivative	Direct	Reported balance After 2025-05-13 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2025-05-13 · Other · Disposed 22,625 · Balance 0 F1: Represents securities that were tendered in connection with the Agreement and Plan of Merger (the "Merger Agreement"), dated March 10, 2025, by and among 2seventy bio, Inc. (the "Company"), Daybreak Merger Sub Inc. ("Merger Sub") and Bristol-Myers Squibb Company ("Parent"). Following completion of a cash tender offer by Merger Sub to acquire all of the issued and outstanding shares of the Company's common stock, par value $0.0001 per share (the "Company Common Stock") for $5.00 per share (the "Merger Consideration"), Merger Sub merged with and into the Company, with the Company continuing as the surviving corporation and a whole owned subsidiary of Parent (the "Merger"). F2: cont'd from footnote (1): Each restricted stock unit in respect of Company Common Stock ("Company RSU Award"), whether vested or unvested, that was outstanding immediately prior to the effective time of the Merger (the "Effective Time") was fully vested, was cancelled and automatically converted into the right to receive, for each share of Company Common Stock underlying such Company RSU Award immediately prior to the Effective Time, an amount (without interest and subject to deduction for any required withholding under applicable law relating to tax) in cash equal to the Merger Consideration. Additionally, effective as of the Effective Time and as a result of the Merger, Eli Casdin ceased to be a member of the Company's board of directors. F3: The securities were owned directly by Eli Casdin.
Common Stock, par value $0.0001 per shareSEC Table I · non-derivative	IndirectSee footnote	Reported balance After 2025-05-13 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 2 · 2025-05-13 · Other · Disposed 2,000,000 · Balance 0 F1: Represents securities that were tendered in connection with the Agreement and Plan of Merger (the "Merger Agreement"), dated March 10, 2025, by and among 2seventy bio, Inc. (the "Company"), Daybreak Merger Sub Inc. ("Merger Sub") and Bristol-Myers Squibb Company ("Parent"). Following completion of a cash tender offer by Merger Sub to acquire all of the issued and outstanding shares of the Company's common stock, par value $0.0001 per share (the "Company Common Stock") for $5.00 per share (the "Merger Consideration"), Merger Sub merged with and into the Company, with the Company continuing as the surviving corporation and a whole owned subsidiary of Parent (the "Merger"). F2: cont'd from footnote (1): Each restricted stock unit in respect of Company Common Stock ("Company RSU Award"), whether vested or unvested, that was outstanding immediately prior to the effective time of the Merger (the "Effective Time") was fully vested, was cancelled and automatically converted into the right to receive, for each share of Company Common Stock underlying such Company RSU Award immediately prior to the Effective Time, an amount (without interest and subject to deduction for any required withholding under applicable law relating to tax) in cash equal to the Merger Consideration. Additionally, effective as of the Effective Time and as a result of the Merger, Eli Casdin ceased to be a member of the Company's board of directors. F4: The securities were owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to have been indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to the Master Fund ("Casdin"), (ii) Casdin Partners GP, LLC, the general partner of the Master Fund (the "GP"), and (iii) Eli Casdin, the managing member of Casdin and the GP.
Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.93	Direct	Reported balance After 2025-05-13 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2025-05-13 · Disposition to issuer · Disposed 12,050 · Balance 0 F5: Each option to purchase Company Common Stock ("Company Option"), whether vested or unvested, that was outstanding and unexercised immediately prior to the Effective Time and had a per share exercise price that was less than the Merger Consideration was fully vested, was cancelled and automatically converted into the right to receive, for each share of Company Common Stock underlying such Company Option immediately prior to the Effective Time, an amount (without interest and subject to deduction for any required withholding under applicable law relating to tax) in cash equal to the excess of the Merger Consideration over the per share exercise price of such Company Option. F3: The securities were owned directly by Eli Casdin.
Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.54	Direct	Reported balance After 2025-05-13 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2025-05-13 · Disposition to issuer · Disposed 33,400 · Balance 0 F5: Each option to purchase Company Common Stock ("Company Option"), whether vested or unvested, that was outstanding and unexercised immediately prior to the Effective Time and had a per share exercise price that was less than the Merger Consideration was fully vested, was cancelled and automatically converted into the right to receive, for each share of Company Common Stock underlying such Company Option immediately prior to the Effective Time, an amount (without interest and subject to deduction for any required withholding under applicable law relating to tax) in cash equal to the excess of the Merger Consideration over the per share exercise price of such Company Option. F3: The securities were owned directly by Eli Casdin.

Filing footnotes · ownership attribution and instrument terms

F1: Represents securities that were tendered in connection with the Agreement and Plan of Merger (the "Merger Agreement"), dated March 10, 2025, by and among 2seventy bio, Inc. (the "Company"), Daybreak Merger Sub Inc. ("Merger Sub") and Bristol-Myers Squibb Company ("Parent"). Following completion of a cash tender offer by Merger Sub to acquire all of the issued and outstanding shares of the Company's common stock, par value $0.0001 per share (the "Company Common Stock") for $5.00 per share (the "Merger Consideration"), Merger Sub merged with and into the Company, with the Company continuing as the surviving corporation and a whole owned subsidiary of Parent (the "Merger").

F2: cont'd from footnote (1): Each restricted stock unit in respect of Company Common Stock ("Company RSU Award"), whether vested or unvested, that was outstanding immediately prior to the effective time of the Merger (the "Effective Time") was fully vested, was cancelled and automatically converted into the right to receive, for each share of Company Common Stock underlying such Company RSU Award immediately prior to the Effective Time, an amount (without interest and subject to deduction for any required withholding under applicable law relating to tax) in cash equal to the Merger Consideration. Additionally, effective as of the Effective Time and as a result of the Merger, Eli Casdin ceased to be a member of the Company's board of directors.

F3: The securities were owned directly by Eli Casdin.

F4: The securities were owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to have been indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to the Master Fund ("Casdin"), (ii) Casdin Partners GP, LLC, the general partner of the Master Fund (the "GP"), and (iii) Eli Casdin, the managing member of Casdin and the GP.

F5: Each option to purchase Company Common Stock ("Company Option"), whether vested or unvested, that was outstanding and unexercised immediately prior to the Effective Time and had a per share exercise price that was less than the Merger Consideration was fully vested, was cancelled and automatically converted into the right to receive, for each share of Company Common Stock underlying such Company Option immediately prior to the Effective Time, an amount (without interest and subject to deduction for any required withholding under applicable law relating to tax) in cash equal to the excess of the Merger Consideration over the per share exercise price of such Company Option.

BIOLIFE SOLUTIONS INC

Report date May 19, 2026 · Filed May 21, 2026

Jointly reported with Casdin Partners Master Fund, L.P., Casdin Capital, LLC, Casdin Partners GP, LLC

Section 16 reporting ended · disclosed 2026-05-21. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common Stock, par value $0.001 per shareSEC Table I · non-derivative	IndirectSee footnote	4,757,165	Last balance in matching sequence After 2026-05-21 transaction · row 3 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 3 source rows Row 1 · 2026-05-19 · Sale · Disposed 300,000 · Balance 5,657,165 F1: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin Capital"), the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC ("Casdin GP"), the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin Capital and Casdin GP. Row 2 · 2026-05-20 · Sale · Disposed 250,000 · Balance 5,407,165 F1: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin Capital"), the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC ("Casdin GP"), the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin Capital and Casdin GP. Row 3 · 2026-05-21 · Sale · Disposed 650,000 · Balance 4,757,165 F1: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin Capital"), the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC ("Casdin GP"), the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin Capital and Casdin GP.

Filing footnotes · ownership attribution and instrument terms

F1: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin Capital"), the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC ("Casdin GP"), the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin Capital and Casdin GP.

CONSTELLATION PHARMACEUTICALS INC

Report date July 23, 2018 · Filed July 23, 2018

Jointly reported with Casdin Capital, LLC, Casdin Partners Master Fund, L.P., Casdin Partners GP, LLC, Casdin Venture Opportunities Fund, L.P., CASDIN VENTURE OPPORTUNITIES FUND GP, LLC

Section 16 reporting ended · disclosed 2018-07-23. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee footnote	345,783	Reported balance After 2018-07-23 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2018-07-23 · Conversion · Acquired 345,783 · Balance 345,783 F1: On July 23, 2018, the Series E-1 and Series F Preferred Stock converted into Common Stock on a 11.009-for-one basis, and the Series E Preferred Stock converted into Common Stock on a 8.56256-for-one basis, upon the closing of the Issuer's initial public offering without payment of consideration. The Series E, Series E-1 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date. F2: These securities are owned directly by Casdin Partners Master Fund, LP and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to Casdin Partners Master Fund, LP, (ii) Casdin Partners GP, LLC, the general partner of Casdin Partners Master Fund LP, and (ii) Eli Casdin, the managing member of Casdin Capital, LLC and Casdin Partners GP, LLC.
Common StockSEC Table I · non-derivative	IndirectSee footnote	612,450	Reported balance After 2018-07-23 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 2 · 2018-07-23 · Purchase · Acquired 266,667 · Balance 612,450 F2: These securities are owned directly by Casdin Partners Master Fund, LP and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to Casdin Partners Master Fund, LP, (ii) Casdin Partners GP, LLC, the general partner of Casdin Partners Master Fund LP, and (ii) Eli Casdin, the managing member of Casdin Capital, LLC and Casdin Partners GP, LLC.
Common StockSEC Table I · non-derivative	IndirectSee footnote	158,960	Reported balance After 2018-07-23 transaction · row 3 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 3 · 2018-07-23 · Conversion · Acquired 158,960 · Balance 158,960 F1: On July 23, 2018, the Series E-1 and Series F Preferred Stock converted into Common Stock on a 11.009-for-one basis, and the Series E Preferred Stock converted into Common Stock on a 8.56256-for-one basis, upon the closing of the Issuer's initial public offering without payment of consideration. The Series E, Series E-1 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date. F3: These securities are owned directly by Casdin Venture Opportunities Fund, LP and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to Casdin Venture Opportunities Fund, LP, (ii) Casdin Venture Opportunities Fund GP, LLC, the general partner of Casdin Venture Opportunities Fund, LP, and (ii) Eli Casdin, the managing member of Casdin Capital, LLC and Casdin Venture Opportunities Fund GP, LLC.
Series E Preferred StockSEC Table II · derivative / convertible security	IndirectSee footnote	0	Reported balance After 2018-07-23 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2018-07-23 · Conversion · Disposed 1,333,333 · Balance 0 F1: On July 23, 2018, the Series E-1 and Series F Preferred Stock converted into Common Stock on a 11.009-for-one basis, and the Series E Preferred Stock converted into Common Stock on a 8.56256-for-one basis, upon the closing of the Issuer's initial public offering without payment of consideration. The Series E, Series E-1 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date. F2: These securities are owned directly by Casdin Partners Master Fund, LP and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to Casdin Partners Master Fund, LP, (ii) Casdin Partners GP, LLC, the general partner of Casdin Partners Master Fund LP, and (ii) Eli Casdin, the managing member of Casdin Capital, LLC and Casdin Partners GP, LLC.
Series E-1 Preferred StockSEC Table II · derivative / convertible security	IndirectSee footnote	0	Reported balance After 2018-07-23 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2018-07-23 · Conversion · Disposed 342,435 · Balance 0 F1: On July 23, 2018, the Series E-1 and Series F Preferred Stock converted into Common Stock on a 11.009-for-one basis, and the Series E Preferred Stock converted into Common Stock on a 8.56256-for-one basis, upon the closing of the Issuer's initial public offering without payment of consideration. The Series E, Series E-1 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date. F2: These securities are owned directly by Casdin Partners Master Fund, LP and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to Casdin Partners Master Fund, LP, (ii) Casdin Partners GP, LLC, the general partner of Casdin Partners Master Fund LP, and (ii) Eli Casdin, the managing member of Casdin Capital, LLC and Casdin Partners GP, LLC.
Series F Preferred StockSEC Table II · derivative / convertible security	IndirectSee footnote	0	Reported balance After 2018-07-23 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2018-07-23 · Conversion · Disposed 1,750,000 · Balance 0 F1: On July 23, 2018, the Series E-1 and Series F Preferred Stock converted into Common Stock on a 11.009-for-one basis, and the Series E Preferred Stock converted into Common Stock on a 8.56256-for-one basis, upon the closing of the Issuer's initial public offering without payment of consideration. The Series E, Series E-1 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date. F2: These securities are owned directly by Casdin Partners Master Fund, LP and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to Casdin Partners Master Fund, LP, (ii) Casdin Partners GP, LLC, the general partner of Casdin Partners Master Fund LP, and (ii) Eli Casdin, the managing member of Casdin Capital, LLC and Casdin Partners GP, LLC.
Series F Preferred StockSEC Table II · derivative / convertible security	IndirectSee footnote	0	Reported balance After 2018-07-23 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2018-07-23 · Conversion · Disposed 1,750,000 · Balance 0 F1: On July 23, 2018, the Series E-1 and Series F Preferred Stock converted into Common Stock on a 11.009-for-one basis, and the Series E Preferred Stock converted into Common Stock on a 8.56256-for-one basis, upon the closing of the Issuer's initial public offering without payment of consideration. The Series E, Series E-1 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date. F3: These securities are owned directly by Casdin Venture Opportunities Fund, LP and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to Casdin Venture Opportunities Fund, LP, (ii) Casdin Venture Opportunities Fund GP, LLC, the general partner of Casdin Venture Opportunities Fund, LP, and (ii) Eli Casdin, the managing member of Casdin Capital, LLC and Casdin Venture Opportunities Fund GP, LLC.

Filing footnotes · ownership attribution and instrument terms

F1: On July 23, 2018, the Series E-1 and Series F Preferred Stock converted into Common Stock on a 11.009-for-one basis, and the Series E Preferred Stock converted into Common Stock on a 8.56256-for-one basis, upon the closing of the Issuer's initial public offering without payment of consideration. The Series E, Series E-1 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date.

F2: These securities are owned directly by Casdin Partners Master Fund, LP and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to Casdin Partners Master Fund, LP, (ii) Casdin Partners GP, LLC, the general partner of Casdin Partners Master Fund LP, and (ii) Eli Casdin, the managing member of Casdin Capital, LLC and Casdin Partners GP, LLC.

F3: These securities are owned directly by Casdin Venture Opportunities Fund, LP and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to Casdin Venture Opportunities Fund, LP, (ii) Casdin Venture Opportunities Fund GP, LLC, the general partner of Casdin Venture Opportunities Fund, LP, and (ii) Eli Casdin, the managing member of Casdin Capital, LLC and Casdin Venture Opportunities Fund GP, LLC.

EQRx, Inc.

Report date November 09, 2023 · Filed November 14, 2023

Section 16 reporting ended · disclosed 2023-11-14. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee footnote	Reported balance After 2023-11-09 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 1 · 2023-11-09 · Other · Disposed 8,659,372 · Balance 0 F1: The securities were held directly by CMLS Holdings III LLC ("CMLS Holdings III"). Mr. Casdin is a member of the Board of Managers of CMLS Holdings III and as a result shares voting and investment discretion with respect to the securities held by CMLS Holdings III. Mr. Casdin disclaims beneficial ownership of these shares except to the extent of his respective pecuniary interest therein.
Common StockSEC Table I · non-derivative	IndirectSee footnote	Reported balance After 2023-11-09 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2023-11-09 · Other · Disposed 30,214,934 · Balance 0 F2: The securities were owned directly by the Casdin Partners Master Fund, L.P. (the "Master Fund") and were deemed to be indirectly beneficially owned by (i) Casdin Capital, the investment adviser to the Master Fund, (ii) Casdin GP, the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin Capital and Casdin GP. Mr. Casdin disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein.)
Common StockSEC Table I · non-derivative	IndirectSee footnote	Reported balance After 2023-11-09 transaction · row 3 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 3 · 2023-11-09 · Other · Disposed 3,824,572 · Balance 0 F3: The securities were owned directly by Casdin Venture Opportunities Fund, L.P. (the "Venture Fund") and were deemed to be indirectly bencially owned by (i) Casdin Capital, the investment adviser to the Venture Fund, (ii) Casdin Venture Opportunities Fund GP, LLC (the "Venture GP"), the general partner of the Venture Fund, and (iii) Eli Casdin, the managing member of Casdin Capital and Venture GP.
Common StockSEC Table I · non-derivative	IndirectSee footnote	Reported balance After 2023-11-09 transaction · row 4 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 4 · 2023-11-09 · Other · Disposed 5,488,164 · Balance 0 F4: The securities were owned directly by Casdin Private Growth Equity Fund, L.P. (the "Private Fund") and were deemed to be indirectly beneficially owned by (i) Casdin Capital, the investment adviser to the Private Fund, (ii) Casdin Private Growth Equity Fund GP, LLC (the "Private GP"), the general partner of the Private Fund, and (iii) Eli Casdin, the managing member of Casdin Capital and Private GP
Warrants to purchase Class A Common Stock (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.50 · Expires 2026-12-17	IndirectSee footnote	Reported balance After 2023-11-09 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2023-11-09 · Other · Disposed 8,110,001 · Balance 0 F1: The securities were held directly by CMLS Holdings III LLC ("CMLS Holdings III"). Mr. Casdin is a member of the Board of Managers of CMLS Holdings III and as a result shares voting and investment discretion with respect to the securities held by CMLS Holdings III. Mr. Casdin disclaims beneficial ownership of these shares except to the extent of his respective pecuniary interest therein.
Earn-out SharesSEC Table II · derivative / convertible security · Expires 2024-12-17	IndirectSee footnote	Reported balance After 2023-11-09 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2023-11-09 · Other · Disposed 3,472,300 · Balance 0 F5: The Reporting Person received the right to acquire an aggregate of 4,729,839 shares of the Issuer's Common Stock (the "Earn-out Shares") (i) 3,310,887 of which were to be released from escrow if the value weighted average price ("VWAP") for at least 20 of any 30 consecutive trading days following December 17, 2022 was at least $12.50; and (ii) 1,418,952 would have been released from such escrow if the VWAP for at least 20 of any 30 consecutive trading days following December 17, 2022 was at least $16.50. Any Earn-out Shares not eligible to be released on or prior to December 17, 2024 would have been forfeited and cancelled, and the maximum number of Earn-out Shares the Reporting Person may be eligible to acquire was subject to adjustment. F2: The securities were owned directly by the Casdin Partners Master Fund, L.P. (the "Master Fund") and were deemed to be indirectly beneficially owned by (i) Casdin Capital, the investment adviser to the Master Fund, (ii) Casdin GP, the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin Capital and Casdin GP. Mr. Casdin disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein.)
Earn-out SharesSEC Table II · derivative / convertible security · Expires 2024-12-17	IndirectSee footnote	Reported balance After 2023-11-09 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2023-11-09 · Other · Disposed 526,674 · Balance 0 F5: The Reporting Person received the right to acquire an aggregate of 4,729,839 shares of the Issuer's Common Stock (the "Earn-out Shares") (i) 3,310,887 of which were to be released from escrow if the value weighted average price ("VWAP") for at least 20 of any 30 consecutive trading days following December 17, 2022 was at least $12.50; and (ii) 1,418,952 would have been released from such escrow if the VWAP for at least 20 of any 30 consecutive trading days following December 17, 2022 was at least $16.50. Any Earn-out Shares not eligible to be released on or prior to December 17, 2024 would have been forfeited and cancelled, and the maximum number of Earn-out Shares the Reporting Person may be eligible to acquire was subject to adjustment. F3: The securities were owned directly by Casdin Venture Opportunities Fund, L.P. (the "Venture Fund") and were deemed to be indirectly bencially owned by (i) Casdin Capital, the investment adviser to the Venture Fund, (ii) Casdin Venture Opportunities Fund GP, LLC (the "Venture GP"), the general partner of the Venture Fund, and (iii) Eli Casdin, the managing member of Casdin Capital and Venture GP.
Earn-out SharesSEC Table II · derivative / convertible security · Expires 2024-12-17	IndirectSee footnote	Reported balance After 2023-11-09 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2023-11-09 · Other · Disposed 755,766 · Balance 0 F5: The Reporting Person received the right to acquire an aggregate of 4,729,839 shares of the Issuer's Common Stock (the "Earn-out Shares") (i) 3,310,887 of which were to be released from escrow if the value weighted average price ("VWAP") for at least 20 of any 30 consecutive trading days following December 17, 2022 was at least $12.50; and (ii) 1,418,952 would have been released from such escrow if the VWAP for at least 20 of any 30 consecutive trading days following December 17, 2022 was at least $16.50. Any Earn-out Shares not eligible to be released on or prior to December 17, 2024 would have been forfeited and cancelled, and the maximum number of Earn-out Shares the Reporting Person may be eligible to acquire was subject to adjustment. F4: The securities were owned directly by Casdin Private Growth Equity Fund, L.P. (the "Private Fund") and were deemed to be indirectly beneficially owned by (i) Casdin Capital, the investment adviser to the Private Fund, (ii) Casdin Private Growth Equity Fund GP, LLC (the "Private GP"), the general partner of the Private Fund, and (iii) Eli Casdin, the managing member of Casdin Capital and Private GP
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.95 · Expires 2032-09-30	Direct	Reported balance After 2023-11-09 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2023-11-09 · Other · Disposed 101,010 · Balance 0 F6: The shares underlying this option vested and became exercisable in full on September 30, 2023, the one-year anniversary of the grant date, subject to the Reporting Person's continuous service on such vesting date, and subject to full acceleration upon the consummation of a Sale Event (as defined in the Issuer's 2021 Stock Option and Incentive Plan).

Filing footnotes · ownership attribution and instrument terms

F1: The securities were held directly by CMLS Holdings III LLC ("CMLS Holdings III"). Mr. Casdin is a member of the Board of Managers of CMLS Holdings III and as a result shares voting and investment discretion with respect to the securities held by CMLS Holdings III. Mr. Casdin disclaims beneficial ownership of these shares except to the extent of his respective pecuniary interest therein.

F2: The securities were owned directly by the Casdin Partners Master Fund, L.P. (the "Master Fund") and were deemed to be indirectly beneficially owned by (i) Casdin Capital, the investment adviser to the Master Fund, (ii) Casdin GP, the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin Capital and Casdin GP. Mr. Casdin disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein.)

F3: The securities were owned directly by Casdin Venture Opportunities Fund, L.P. (the "Venture Fund") and were deemed to be indirectly bencially owned by (i) Casdin Capital, the investment adviser to the Venture Fund, (ii) Casdin Venture Opportunities Fund GP, LLC (the "Venture GP"), the general partner of the Venture Fund, and (iii) Eli Casdin, the managing member of Casdin Capital and Venture GP.

F4: The securities were owned directly by Casdin Private Growth Equity Fund, L.P. (the "Private Fund") and were deemed to be indirectly beneficially owned by (i) Casdin Capital, the investment adviser to the Private Fund, (ii) Casdin Private Growth Equity Fund GP, LLC (the "Private GP"), the general partner of the Private Fund, and (iii) Eli Casdin, the managing member of Casdin Capital and Private GP

F5: The Reporting Person received the right to acquire an aggregate of 4,729,839 shares of the Issuer's Common Stock (the "Earn-out Shares") (i) 3,310,887 of which were to be released from escrow if the value weighted average price ("VWAP") for at least 20 of any 30 consecutive trading days following December 17, 2022 was at least $12.50; and (ii) 1,418,952 would have been released from such escrow if the VWAP for at least 20 of any 30 consecutive trading days following December 17, 2022 was at least $16.50. Any Earn-out Shares not eligible to be released on or prior to December 17, 2024 would have been forfeited and cancelled, and the maximum number of Earn-out Shares the Reporting Person may be eligible to acquire was subject to adjustment.

F6: The shares underlying this option vested and became exercisable in full on September 30, 2023, the one-year anniversary of the grant date, subject to the Reporting Person's continuous service on such vesting date, and subject to full acceleration upon the consummation of a Sale Event (as defined in the Issuer's 2021 Stock Option and Incentive Plan).

Fulcrum Therapeutics, Inc.

Report date July 22, 2019 · Filed July 22, 2019

Jointly reported with Casdin Capital, LLC, Casdin Partners Master Fund, L.P., Casdin Partners GP, LLC

Section 16 reporting ended · disclosed 2019-07-22. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee footnote	604,285	Last balance in matching sequence After 2019-07-22 transaction · row 4 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 4 source rows Row 1 · 2019-07-22 · Conversion · Acquired 464,285 · Balance 464,285 F1: On July 22, 2019, the Series B Preferred Stock converted into Common Stock on a seven-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F2: The securities are owned directly by Casdin Partners Master Fund, LP and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to Casdin Partners Master Fund, LP, (ii) Casdin Partners GP, LLC, the general partner of Casdin Partners Master Fund LP, and (ii) Eli Casdin, the managing member of Casdin Capital, LLC and Casdin Partners GP, LLC. Row 2 · 2019-07-22 · Purchase · Acquired 125,000 · Balance 589,285 F2: The securities are owned directly by Casdin Partners Master Fund, LP and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to Casdin Partners Master Fund, LP, (ii) Casdin Partners GP, LLC, the general partner of Casdin Partners Master Fund LP, and (ii) Eli Casdin, the managing member of Casdin Capital, LLC and Casdin Partners GP, LLC. Row 3 · 2019-07-22 · Purchase · Acquired 10,000 · Balance 599,285 F2: The securities are owned directly by Casdin Partners Master Fund, LP and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to Casdin Partners Master Fund, LP, (ii) Casdin Partners GP, LLC, the general partner of Casdin Partners Master Fund LP, and (ii) Eli Casdin, the managing member of Casdin Capital, LLC and Casdin Partners GP, LLC. Row 4 · 2019-07-22 · Purchase · Acquired 5,000 · Balance 604,285 F2: The securities are owned directly by Casdin Partners Master Fund, LP and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to Casdin Partners Master Fund, LP, (ii) Casdin Partners GP, LLC, the general partner of Casdin Partners Master Fund LP, and (ii) Eli Casdin, the managing member of Casdin Capital, LLC and Casdin Partners GP, LLC.
Series B Preferred StockSEC Table II · derivative / convertible security	IndirectSee footnote	0	Reported balance After 2019-07-22 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2019-07-22 · Conversion · Disposed 3,250,000 · Balance 0 F1: On July 22, 2019, the Series B Preferred Stock converted into Common Stock on a seven-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F2: The securities are owned directly by Casdin Partners Master Fund, LP and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to Casdin Partners Master Fund, LP, (ii) Casdin Partners GP, LLC, the general partner of Casdin Partners Master Fund LP, and (ii) Eli Casdin, the managing member of Casdin Capital, LLC and Casdin Partners GP, LLC.

Filing footnotes · ownership attribution and instrument terms

F1: On July 22, 2019, the Series B Preferred Stock converted into Common Stock on a seven-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.

F2: The securities are owned directly by Casdin Partners Master Fund, LP and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to Casdin Partners Master Fund, LP, (ii) Casdin Partners GP, LLC, the general partner of Casdin Partners Master Fund LP, and (ii) Eli Casdin, the managing member of Casdin Capital, LLC and Casdin Partners GP, LLC.

Generation Bio Co.

Report date June 16, 2020 · Filed June 18, 2020

Jointly reported with Casdin Capital, LLC

Section 16 reporting ended · disclosed 2020-06-18. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee Footnote	1,611,215	Last balance in matching sequence After 2020-06-16 transaction · row 2 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 2 source rows Row 1 · 2020-06-16 · Conversion · Acquired 961,215 · Balance 961,215 F1: On June 16, 2020, the Series B Preferred Stock automatically converted into Common Stock on approximately a 1.5546-for-one basis (when rounded to the nearest ten-thousandth) without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F2: On June 16, 2020, the Series C Preferred Stock automatically converted into Common Stock on a 1.7663-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F3: The securities are owned directly by clients of Casdin Capital, LLC and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC as investment adviser to such clients and (ii) Eli Casdin as managing member of Casdin Capital, LLC. Row 2 · 2020-06-16 · Purchase · Acquired 650,000 · Balance 1,611,215 F3: The securities are owned directly by clients of Casdin Capital, LLC and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC as investment adviser to such clients and (ii) Eli Casdin as managing member of Casdin Capital, LLC.
Series B Preferred StockSEC Table II · derivative / convertible security	IndirectSee Footnote	0	Reported balance After 2020-06-16 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2020-06-16 · Conversion · Disposed 1,093,410 · Balance 0 F1: On June 16, 2020, the Series B Preferred Stock automatically converted into Common Stock on approximately a 1.5546-for-one basis (when rounded to the nearest ten-thousandth) without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F3: The securities are owned directly by clients of Casdin Capital, LLC and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC as investment adviser to such clients and (ii) Eli Casdin as managing member of Casdin Capital, LLC.
Series C Preferred StockSEC Table II · derivative / convertible security	IndirectSee Footnote	0	Reported balance After 2020-06-16 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2020-06-16 · Conversion · Disposed 455,500 · Balance 0 F2: On June 16, 2020, the Series C Preferred Stock automatically converted into Common Stock on a 1.7663-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F3: The securities are owned directly by clients of Casdin Capital, LLC and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC as investment adviser to such clients and (ii) Eli Casdin as managing member of Casdin Capital, LLC.

Filing footnotes · ownership attribution and instrument terms

F1: On June 16, 2020, the Series B Preferred Stock automatically converted into Common Stock on approximately a 1.5546-for-one basis (when rounded to the nearest ten-thousandth) without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.

F2: On June 16, 2020, the Series C Preferred Stock automatically converted into Common Stock on a 1.7663-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.

F3: The securities are owned directly by clients of Casdin Capital, LLC and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC as investment adviser to such clients and (ii) Eli Casdin as managing member of Casdin Capital, LLC.

MAXCYTE, INC.

Report date October 03, 2022 · Filed October 05, 2022

Jointly reported with Casdin Partners Master Fund, L.P., Casdin Capital, LLC, Casdin Partners GP, LLC

Section 16 reporting ended · disclosed 2022-10-05. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common Stock, par value $0.01 per shareSEC Table I · non-derivative	Direct	10,000,000	Reported balance After 2022-10-03 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2022-10-03 · Sale · Disposed 735,786 · Balance 10,000,000 F1: (1) The securities are owned directly by Casdin Partners Master Fund, LP (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC, the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin Capital, LLC and Casdin Partners GP, LLC.

Filing footnotes · ownership attribution and instrument terms

F1: (1) The securities are owned directly by Casdin Partners Master Fund, LP (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC, the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin Capital, LLC and Casdin Partners GP, LLC.

SomaLogic, Inc.

Report date January 05, 2024 · Filed January 10, 2024

Section 16 reporting ended · disclosed 2024-01-10. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2024-01-05 transaction · row 1 1 source row Row 1 · 2024-01-05 · Disposition to issuer · Disposed 3,430 · Balance 0 F1: On October 4, 2023, SomaLogic, Inc., a Delaware corporation (the "Company") entered into the Agreement and Plan of Merger (the "Merger Agreement"), with Standard BioTools Inc., a Delaware corporation ("Parent"), and Martis Merger Sub, Inc., a Delaware corporation and a wholly owned Subsidiary of Parent (the "Merger Sub"). Pursuant to the Merger Agreement, on January 5, 2024, Merger Sub merged with and into the Company, with the Company surviving as a wholly-owned subsidiary of Parent (the "Merger"). F2: (Continued from Footnote 1) At the effective time of the Merger (the "Effective Time"), each share of the Company's common stock, par value $0.0001 per share (the "Company Common Stock"), was converted into the right to receive 1.11 shares (the "Exchange Ratio") of the Parent's common stock, par value $0.001(the "Parent Common Stock") and cash in lieu of fractional shares of the Parent Common Stock.
Common StockSEC Table I · non-derivative	IndirectBy CMLS Holdings II LLC	Reported balance After 2024-01-05 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2024-01-05 · Disposition to issuer · Disposed 6,800,000 · Balance 0 F1: On October 4, 2023, SomaLogic, Inc., a Delaware corporation (the "Company") entered into the Agreement and Plan of Merger (the "Merger Agreement"), with Standard BioTools Inc., a Delaware corporation ("Parent"), and Martis Merger Sub, Inc., a Delaware corporation and a wholly owned Subsidiary of Parent (the "Merger Sub"). Pursuant to the Merger Agreement, on January 5, 2024, Merger Sub merged with and into the Company, with the Company surviving as a wholly-owned subsidiary of Parent (the "Merger"). F2: (Continued from Footnote 1) At the effective time of the Merger (the "Effective Time"), each share of the Company's common stock, par value $0.0001 per share (the "Company Common Stock"), was converted into the right to receive 1.11 shares (the "Exchange Ratio") of the Parent's common stock, par value $0.001(the "Parent Common Stock") and cash in lieu of fractional shares of the Parent Common Stock. F3: The shares are held of record by CMLS Holdings II LLC ("CMLS Holdings II"). The Board of Managers of CMLS Holdings II includes Mr. Casdin, who, as a member of the Board of Managers of CMLS Holdings II, shares voting and investment discretion with respect to the common stock held by CMLS Holdings II. Mr. Casdin may be deemed to have or share beneficial ownership of the securities held by CMLS Holdings II, which include such shares and the warrants referenced in Table II.
Common StockSEC Table I · non-derivative	IndirectBy Casdin Master Fund, L.P.	Reported balance After 2024-01-05 transaction · row 3 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 3 · 2024-01-05 · Disposition to issuer · Disposed 10,132,005 · Balance 0 F1: On October 4, 2023, SomaLogic, Inc., a Delaware corporation (the "Company") entered into the Agreement and Plan of Merger (the "Merger Agreement"), with Standard BioTools Inc., a Delaware corporation ("Parent"), and Martis Merger Sub, Inc., a Delaware corporation and a wholly owned Subsidiary of Parent (the "Merger Sub"). Pursuant to the Merger Agreement, on January 5, 2024, Merger Sub merged with and into the Company, with the Company surviving as a wholly-owned subsidiary of Parent (the "Merger"). F2: (Continued from Footnote 1) At the effective time of the Merger (the "Effective Time"), each share of the Company's common stock, par value $0.0001 per share (the "Company Common Stock"), was converted into the right to receive 1.11 shares (the "Exchange Ratio") of the Parent's common stock, par value $0.001(the "Parent Common Stock") and cash in lieu of fractional shares of the Parent Common Stock. F4: The securities are owned directly by Casdin Partners Master Fund, LP (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC, the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin Capital, LLC and Casdin Partners GP, LLC.
Common StockSEC Table I · non-derivative	IndirectBy Casdin Private Growth Equity Fund, L.P.	Reported balance After 2024-01-05 transaction · row 4 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 4 · 2024-01-05 · Disposition to issuer · Disposed 2,472,270 · Balance 0 F1: On October 4, 2023, SomaLogic, Inc., a Delaware corporation (the "Company") entered into the Agreement and Plan of Merger (the "Merger Agreement"), with Standard BioTools Inc., a Delaware corporation ("Parent"), and Martis Merger Sub, Inc., a Delaware corporation and a wholly owned Subsidiary of Parent (the "Merger Sub"). Pursuant to the Merger Agreement, on January 5, 2024, Merger Sub merged with and into the Company, with the Company surviving as a wholly-owned subsidiary of Parent (the "Merger"). F2: (Continued from Footnote 1) At the effective time of the Merger (the "Effective Time"), each share of the Company's common stock, par value $0.0001 per share (the "Company Common Stock"), was converted into the right to receive 1.11 shares (the "Exchange Ratio") of the Parent's common stock, par value $0.001(the "Parent Common Stock") and cash in lieu of fractional shares of the Parent Common Stock. F5: The shares held by Casdin Private Growth Equity Fund, L.P. may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to Casdin Private Growth Equity Fund, L.P., (ii) Casdin Private Growth Equity GP, LLC, the general partner of Casdin Private Growth Equity Fund, L.P., and (iii) Eli Casdin, the managing member of Casdin Capital, LLC and Casdin Private Growth Equity GP, LLC.
Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.77 · Expires 2031-02-18	Direct	Reported balance After 2024-01-05 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2024-01-05 · Disposition to issuer · Disposed 41,905 · Balance 0 F7: Pursuant to the Merger Agreement, each option to purchase Company Common Stock (a "Company Option"), whether vested or unvested, that was outstanding immediately prior to the Effective Time, was converted into an option to acquire the number of shares of Parent Common Stock equal to the product of (i) the number of shares subject to such Company Option as of immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, rounded down to the nearest whole number of shares of the Parent Common Stock, at an exercise price per share equal to the quotient obtained by dividing the per share exercise price of the Company Option by the Exchange Ratio, rounded up to the nearest whole cent. Each such Company Option shall continue to have, and be subject to, the same terms and conditions applicable to such Company Option immediately prior to the Effective Time, including vesting terms and provisions. F6: The option vested as to 1/4th of the total grant on February 19, 2022, and thereafter 1/36th of the total grant vests monthly until such time as the option is 100% vested, subject to the continued service of the Reporting Person on each vesting date.
Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.85 · Expires 2031-10-26	Direct	Reported balance After 2024-01-05 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2024-01-05 · Disposition to issuer · Disposed 46,705 · Balance 0 F7: Pursuant to the Merger Agreement, each option to purchase Company Common Stock (a "Company Option"), whether vested or unvested, that was outstanding immediately prior to the Effective Time, was converted into an option to acquire the number of shares of Parent Common Stock equal to the product of (i) the number of shares subject to such Company Option as of immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, rounded down to the nearest whole number of shares of the Parent Common Stock, at an exercise price per share equal to the quotient obtained by dividing the per share exercise price of the Company Option by the Exchange Ratio, rounded up to the nearest whole cent. Each such Company Option shall continue to have, and be subject to, the same terms and conditions applicable to such Company Option immediately prior to the Effective Time, including vesting terms and provisions. F8: The option vested as to 1/4th of the total grant on October 27, 2022, and thereafter 1/36th of the total grant vests monthly until such time as the option is 100% vested, subject to the continued service of the Reporting Person on each vesting date.
Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.08 · Expires 2032-02-29	Direct	Reported balance After 2024-01-05 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2024-01-05 · Disposition to issuer · Disposed 20,600 · Balance 0 F7: Pursuant to the Merger Agreement, each option to purchase Company Common Stock (a "Company Option"), whether vested or unvested, that was outstanding immediately prior to the Effective Time, was converted into an option to acquire the number of shares of Parent Common Stock equal to the product of (i) the number of shares subject to such Company Option as of immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, rounded down to the nearest whole number of shares of the Parent Common Stock, at an exercise price per share equal to the quotient obtained by dividing the per share exercise price of the Company Option by the Exchange Ratio, rounded up to the nearest whole cent. Each such Company Option shall continue to have, and be subject to, the same terms and conditions applicable to such Company Option immediately prior to the Effective Time, including vesting terms and provisions. F9: The option is fully vested and exercisable.
Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.30 · Expires 2033-03-16	Direct	Reported balance After 2024-01-05 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2024-01-05 · Disposition to issuer · Disposed 20,600 · Balance 0 F7: Pursuant to the Merger Agreement, each option to purchase Company Common Stock (a "Company Option"), whether vested or unvested, that was outstanding immediately prior to the Effective Time, was converted into an option to acquire the number of shares of Parent Common Stock equal to the product of (i) the number of shares subject to such Company Option as of immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, rounded down to the nearest whole number of shares of the Parent Common Stock, at an exercise price per share equal to the quotient obtained by dividing the per share exercise price of the Company Option by the Exchange Ratio, rounded up to the nearest whole cent. Each such Company Option shall continue to have, and be subject to, the same terms and conditions applicable to such Company Option immediately prior to the Effective Time, including vesting terms and provisions. F10: The option shall be 100% vested on March 17, 2024, subject to the continued service of the Reporting Person on such vesting date.
Restricted Stock UnitSEC Table II · derivative / convertible security	Direct	Reported balance After 2024-01-05 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2024-01-05 · Disposition to issuer · Disposed 3,430 · Balance 0 F11: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company Common Stock upon settlement for no consideration. F13: Pursuant to the Merger Agreement, each RSU convertible into shares of Company Common Stock (a "Company RSU") that was outstanding immediately prior to the Effective Time, was converted into an RSU to acquire the number of shares of Parent Common Stock equal to the to the product of (i) the number of shares subject to such Company RSU as of immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, with the resulting number of shares of Parent Common Stock rounded to the next nearest whole share. Except as noted above, each assumed Company RSU will continue to be governed by the same terms and conditions, including vesting terms and provision, as were applicable to such Company RSU immediately prior to the Effective Time. F12: The RSUs shall be 100% vested on March 17, 2024, subject to the continued service of the Reporting Person on such vesting date.
Warrant to purchase common stock (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.50 · Expires 2026-09-01	IndirectBy CMLS Holdings II LLC	Reported balance After 2024-01-05 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2024-01-05 · Disposition to issuer · Disposed 4,346,669 · Balance 0 F15: Pursuant to the Merger Agreement, each warrant to purchase Company Common Stock was treated in accordance with its terms on and after the Effective Time and each warrant will convert into the right to receive, upon exercise of such warrant, the number of shares of Parent Common Stock equal to multiplying the number of shares of Company Common Stock subject to such warrant by the Exchange Ratio. F14: Each warrant is exercisable to purchase one share of Company Common Stock at a price of $11.50 per share, subject to adjustment, as described in the Issuer's Annual Report on Form 10-K, for the fiscal year ended December 31, 2022, filed with the Securities and Exchange Commission on March 28, 2023. F3: The shares are held of record by CMLS Holdings II LLC ("CMLS Holdings II"). The Board of Managers of CMLS Holdings II includes Mr. Casdin, who, as a member of the Board of Managers of CMLS Holdings II, shares voting and investment discretion with respect to the common stock held by CMLS Holdings II. Mr. Casdin may be deemed to have or share beneficial ownership of the securities held by CMLS Holdings II, which include such shares and the warrants referenced in Table II.

Filing footnotes · ownership attribution and instrument terms

F1: On October 4, 2023, SomaLogic, Inc., a Delaware corporation (the "Company") entered into the Agreement and Plan of Merger (the "Merger Agreement"), with Standard BioTools Inc., a Delaware corporation ("Parent"), and Martis Merger Sub, Inc., a Delaware corporation and a wholly owned Subsidiary of Parent (the "Merger Sub"). Pursuant to the Merger Agreement, on January 5, 2024, Merger Sub merged with and into the Company, with the Company surviving as a wholly-owned subsidiary of Parent (the "Merger").

F2: (Continued from Footnote 1) At the effective time of the Merger (the "Effective Time"), each share of the Company's common stock, par value $0.0001 per share (the "Company Common Stock"), was converted into the right to receive 1.11 shares (the "Exchange Ratio") of the Parent's common stock, par value $0.001(the "Parent Common Stock") and cash in lieu of fractional shares of the Parent Common Stock.

F3: The shares are held of record by CMLS Holdings II LLC ("CMLS Holdings II"). The Board of Managers of CMLS Holdings II includes Mr. Casdin, who, as a member of the Board of Managers of CMLS Holdings II, shares voting and investment discretion with respect to the common stock held by CMLS Holdings II. Mr. Casdin may be deemed to have or share beneficial ownership of the securities held by CMLS Holdings II, which include such shares and the warrants referenced in Table II.

F4: The securities are owned directly by Casdin Partners Master Fund, LP (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC, the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin Capital, LLC and Casdin Partners GP, LLC.

F5: The shares held by Casdin Private Growth Equity Fund, L.P. may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to Casdin Private Growth Equity Fund, L.P., (ii) Casdin Private Growth Equity GP, LLC, the general partner of Casdin Private Growth Equity Fund, L.P., and (iii) Eli Casdin, the managing member of Casdin Capital, LLC and Casdin Private Growth Equity GP, LLC.

F6: The option vested as to 1/4th of the total grant on February 19, 2022, and thereafter 1/36th of the total grant vests monthly until such time as the option is 100% vested, subject to the continued service of the Reporting Person on each vesting date.

F7: Pursuant to the Merger Agreement, each option to purchase Company Common Stock (a "Company Option"), whether vested or unvested, that was outstanding immediately prior to the Effective Time, was converted into an option to acquire the number of shares of Parent Common Stock equal to the product of (i) the number of shares subject to such Company Option as of immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, rounded down to the nearest whole number of shares of the Parent Common Stock, at an exercise price per share equal to the quotient obtained by dividing the per share exercise price of the Company Option by the Exchange Ratio, rounded up to the nearest whole cent. Each such Company Option shall continue to have, and be subject to, the same terms and conditions applicable to such Company Option immediately prior to the Effective Time, including vesting terms and provisions.

F8: The option vested as to 1/4th of the total grant on October 27, 2022, and thereafter 1/36th of the total grant vests monthly until such time as the option is 100% vested, subject to the continued service of the Reporting Person on each vesting date.

F9: The option is fully vested and exercisable.

F10: The option shall be 100% vested on March 17, 2024, subject to the continued service of the Reporting Person on such vesting date.

F11: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company Common Stock upon settlement for no consideration.

F12: The RSUs shall be 100% vested on March 17, 2024, subject to the continued service of the Reporting Person on such vesting date.

F13: Pursuant to the Merger Agreement, each RSU convertible into shares of Company Common Stock (a "Company RSU") that was outstanding immediately prior to the Effective Time, was converted into an RSU to acquire the number of shares of Parent Common Stock equal to the to the product of (i) the number of shares subject to such Company RSU as of immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, with the resulting number of shares of Parent Common Stock rounded to the next nearest whole share. Except as noted above, each assumed Company RSU will continue to be governed by the same terms and conditions, including vesting terms and provision, as were applicable to such Company RSU immediately prior to the Effective Time.

F14: Each warrant is exercisable to purchase one share of Company Common Stock at a price of $11.50 per share, subject to adjustment, as described in the Issuer's Annual Report on Form 10-K, for the fiscal year ended December 31, 2022, filed with the Securities and Exchange Commission on March 28, 2023.

F15: Pursuant to the Merger Agreement, each warrant to purchase Company Common Stock was treated in accordance with its terms on and after the Effective Time and each warrant will convert into the right to receive, upon exercise of such warrant, the number of shares of Parent Common Stock equal to multiplying the number of shares of Company Common Stock subject to such warrant by the Exchange Ratio.

Tenaya Therapeutics, Inc.

Report date November 17, 2022 · Filed November 26, 2022

Jointly reported with Casdin Capital, LLC

Section 16 reporting ended · disclosed 2022-11-26. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee footnote	6,078,860	Reported balance After 2022-11-17 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2022-11-17 · Purchase · Acquired 2,492,042 · Balance 6,078,860 F1: The securities are owned directly by clients of Casdin Capital, LLC ("Casdin Capital") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, the investment adviser to such clients and (ii) Eli Casdin, the managing member of Casdin Capital.
WarrantSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	IndirectSee footnote	1,354,111	Reported balance After 2022-11-17 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2022-11-17 · Purchase · Acquired 1,354,111 · Balance 1,354,111 F2: Each Warrant will be exercisable on or after the date of issuance until the date the Warrant is exercised in full. Each Warrant will be exercisable, in the holder's discretion, by (i) payment in full in immediately available funds for the number of shares of common stock purchased upon such exercise or (ii) a cashless exercise, in which case the holder would receive upon such exercise the net number of shares of common stock determined according to a pre-set formula. F1: The securities are owned directly by clients of Casdin Capital, LLC ("Casdin Capital") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, the investment adviser to such clients and (ii) Eli Casdin, the managing member of Casdin Capital.

Filing footnotes · ownership attribution and instrument terms

F1: The securities are owned directly by clients of Casdin Capital, LLC ("Casdin Capital") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, the investment adviser to such clients and (ii) Eli Casdin, the managing member of Casdin Capital.

F2: Each Warrant will be exercisable on or after the date of issuance until the date the Warrant is exercised in full. Each Warrant will be exercisable, in the holder's discretion, by (i) payment in full in immediately available funds for the number of shares of common stock purchased upon such exercise or (ii) a cashless exercise, in which case the holder would receive upon such exercise the net number of shares of common stock determined according to a pre-set formula.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
August 09, 2023 Filed Aug 11, 2023 21:01 UTC	BIOLIFE SOLUTIONS INC BLFS · Entity 4614	PurchaseCommon Stock, par value $.001 per share	58,465	$13.20	$771,743.85	Disclosure SEC source: 0000919574-23-004543 · ownership.xml · nonDerivative · entry 1 Casdin Partners Master Fund, L.P. · CIK 0001534265 · 10% owner Casdin Capital, LLC · CIK 0001534261 · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · 10% owner Casdin Eli · CIK 0001534264 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,630,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions within the range of $13.1151 to $13.3998. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. F2 · ownership.direct: The securities are owned directly by the Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin Capital"), the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC ("Casdin GP"), the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin Capital and Casdin GP. Read SEC document
July 21, 2023 Filed Jul 25, 2023 20:14 UTC	GeneDx Holdings Corp. WGS · Entity 1634	GrantRestricted Stock Unit · Derivative	5,828	$0.00	$0.00	Disclosure SEC source: 0001209191-23-043294 · doc4.xml · derivative · entry 2 Casdin Eli · CIK 0001534264 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,828 Underlying: Class A Common Stock · 5,828 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. F3 · derivative.exercise_date: The RSUs shall vest the earlier of (a) the date of the next annual meeting of the Issuer's shareholders following the grant date, and (b) the first anniversary of the grant date, subject to the Reporting Person continuing to provide services to the Issuer through each vesting date. F3 · derivative.expiration_date: The RSUs shall vest the earlier of (a) the date of the next annual meeting of the Issuer's shareholders following the grant date, and (b) the first anniversary of the grant date, subject to the Reporting Person continuing to provide services to the Issuer through each vesting date. Read SEC document
July 21, 2023 Filed Jul 25, 2023 20:14 UTC	GeneDx Holdings Corp. WGS · Entity 1634	GrantStock Option (Right to Buy) · Derivative	8,816	$0.00 Strike: $7.89	$0.00	Disclosure SEC source: 0001209191-23-043294 · doc4.xml · derivative · entry 1 Casdin Eli · CIK 0001534264 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,816 Underlying: Class A Common Stock · 8,816 shares Expires 2033-07-20 F1 · derivative.exercise_date: The stock option shall vest the earlier of (a) the date of the next annual meeting of the Issuer's shareholders following the grant date, and (b) the first anniversary of the grant date, subject to the Reporting Person continuing to provide services to the Issuer through each vesting date. Read SEC document
June 14, 2023 Filed Jun 17, 2023 00:49 UTC	STANDARD BIOTOOLS INC. LAB · Entity 6116	GrantStock Option (Right to Buy) · Derivative	35,380	$0.00 Strike: $2.18	$0.00	Disclosure SEC source: 0001162194-23-000048 · wk-form4_1686962930.xml · derivative · entry 3 Casdin Eli · CIK 0001534264 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,380 Underlying: Common Stock · 35,380 shares Expires 2033-06-14 F3 · derivative.exercise_date: The Option becomes exercisable in twelve equal monthly increments beginning on July 14, 2023 subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document
June 14, 2023 Filed Jun 17, 2023 00:49 UTC	STANDARD BIOTOOLS INC. LAB · Entity 6116	GrantCommon Stock	26,376	$0.00	$0.00	Disclosure SEC source: 0001162194-23-000048 · wk-form4_1686962930.xml · nonDerivative · entry 1 Casdin Eli · CIK 0001534264 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 73,142 F1 · shares: Consists of Restricted Stock Units. Each Restricted Stock Unit represents the right to receive one share of common stock upon vesting. The Restricted Stock Units vest in full on the earlier to occur of June 14, 2024 and one day prior to the date of the Company's next annual meeting of stockholders subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document
May 22, 2023 Filed May 23, 2023 21:46 UTC	BIOLIFE SOLUTIONS INC BLFS · Entity 4614	PurchaseCommon Stock, par value $.001 per share	24,973	$21.86	$545,789.91	Disclosure SEC source: 0000919574-23-003449 · ownership.xml · nonDerivative · entry 2 Casdin Partners Master Fund, L.P. · CIK 0001534265 · 10% owner Casdin Capital, LLC · CIK 0001534261 · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · 10% owner Casdin Eli · CIK 0001534264 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 150,000 F2 · ownership.nature: The securities are owned directly by a client of Casdin Capital, LLC ("Casdin Capital") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, the investment adviser to such client; (ii) Casdin Partners GP, LLC ("Casdin GP"), the general partner of such client, and (iii) Eli Casdin, the managing member of Casdin Capital and Casdin GP. Read SEC document
May 19, 2023 Filed May 20, 2023 01:02 UTC	STANDARD BIOTOOLS INC. LAB · Entity 6116	PurchaseCommon Stock	800,000	$2.29	$1,835,920.00	Disclosure SEC source: 0000919574-23-003426 · ownership.xml · nonDerivative · entry 3 Casdin Eli · CIK 0001534264 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 1,200,000 F4 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions within the range of $2.29 to $2.2982. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. F2 · ownership.nature: The securities are owned directly by Casdin Partners FO1-MSV, LP ("Casdin FO1") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to Casdin FO1, (ii) Casdin Partners GP, LLC, the general partner of Casdin FO1, and (iii) Eli Casdin, the managing member of Casdin Capital, LLC and Casdin Partners GP, LLC. Read SEC document
May 19, 2023 Filed May 23, 2023 21:46 UTC	BIOLIFE SOLUTIONS INC BLFS · Entity 4614	PurchaseCommon Stock, par value $.001 per share	50,000	$22.55	$1,127,430.00	Disclosure SEC source: 0000919574-23-003449 · ownership.xml · nonDerivative · entry 1 Casdin Partners Master Fund, L.P. · CIK 0001534265 · 10% owner Casdin Capital, LLC · CIK 0001534261 · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · 10% owner Casdin Eli · CIK 0001534264 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 125,027 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions within the range of $22.07753 to $23.0197. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. F2 · ownership.nature: The securities are owned directly by a client of Casdin Capital, LLC ("Casdin Capital") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, the investment adviser to such client; (ii) Casdin Partners GP, LLC ("Casdin GP"), the general partner of such client, and (iii) Eli Casdin, the managing member of Casdin Capital and Casdin GP. Read SEC document
May 18, 2023 Filed May 19, 2023 00:31 UTC	BIOLIFE SOLUTIONS INC BLFS · Entity 4614	PurchaseCommon Stock, par value $.001 per share	30,000	$21.76	$652,692.00	Disclosure SEC source: 0000919574-23-003408 · ownership.xml · nonDerivative · entry 3 Casdin Partners Master Fund, L.P. · CIK 0001534265 · 10% owner Casdin Capital, LLC · CIK 0001534261 · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · 10% owner Casdin Eli · CIK 0001534264 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 75,027 F2 · ownership.nature: The securities are owned directly by a client of Casdin Capital, LLC ("Casdin Capital") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, the investment adviser to such client; (ii) Casdin Partners GP, LLC ("Casdin GP"), the general partner of such client, and (iii) Eli Casdin, the managing member of Casdin Capital and Casdin GP. Read SEC document
May 18, 2023 Filed May 20, 2023 01:02 UTC	STANDARD BIOTOOLS INC. LAB · Entity 6116	PurchaseCommon Stock	150,000	$2.16	$323,865.00	Disclosure SEC source: 0000919574-23-003426 · ownership.xml · nonDerivative · entry 2 Casdin Eli · CIK 0001534264 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 400,000 F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions within the range of $2.1489 to $2.1759. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. F2 · ownership.nature: The securities are owned directly by Casdin Partners FO1-MSV, LP ("Casdin FO1") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to Casdin FO1, (ii) Casdin Partners GP, LLC, the general partner of Casdin FO1, and (iii) Eli Casdin, the managing member of Casdin Capital, LLC and Casdin Partners GP, LLC. Read SEC document
May 17, 2023 Filed May 19, 2023 00:31 UTC	BIOLIFE SOLUTIONS INC BLFS · Entity 4614	PurchaseCommon Stock, par value $.001 per share	30,027	$21.30	$639,445.98	Disclosure SEC source: 0000919574-23-003408 · ownership.xml · nonDerivative · entry 2 Casdin Partners Master Fund, L.P. · CIK 0001534265 · 10% owner Casdin Capital, LLC · CIK 0001534261 · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · 10% owner Casdin Eli · CIK 0001534264 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 45,027 F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions within the range of $20.98 to $21.8582. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. F2 · ownership.nature: The securities are owned directly by a client of Casdin Capital, LLC ("Casdin Capital") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, the investment adviser to such client; (ii) Casdin Partners GP, LLC ("Casdin GP"), the general partner of such client, and (iii) Eli Casdin, the managing member of Casdin Capital and Casdin GP. Read SEC document
May 17, 2023 Filed May 20, 2023 01:02 UTC	STANDARD BIOTOOLS INC. LAB · Entity 6116	PurchaseCommon Stock	250,000	$1.89	$471,550.00	Disclosure SEC source: 0000919574-23-003426 · ownership.xml · nonDerivative · entry 1 Casdin Eli · CIK 0001534264 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 250,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions within the range of $1.855 to $1.9237. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. F2 · ownership.nature: The securities are owned directly by Casdin Partners FO1-MSV, LP ("Casdin FO1") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to Casdin FO1, (ii) Casdin Partners GP, LLC, the general partner of Casdin FO1, and (iii) Eli Casdin, the managing member of Casdin Capital, LLC and Casdin Partners GP, LLC. Read SEC document
May 16, 2023 Filed May 19, 2023 00:31 UTC	BIOLIFE SOLUTIONS INC BLFS · Entity 4614	PurchaseCommon Stock, par value $.001 per share	15,000	$20.19	$302,835.00	Disclosure SEC source: 0000919574-23-003408 · ownership.xml · nonDerivative · entry 1 Casdin Partners Master Fund, L.P. · CIK 0001534265 · 10% owner Casdin Capital, LLC · CIK 0001534261 · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · 10% owner Casdin Eli · CIK 0001534264 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 15,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions within the range of $20.1643 to $20.2385. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. F2 · ownership.nature: The securities are owned directly by a client of Casdin Capital, LLC ("Casdin Capital") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, the investment adviser to such client; (ii) Casdin Partners GP, LLC ("Casdin GP"), the general partner of such client, and (iii) Eli Casdin, the managing member of Casdin Capital and Casdin GP. Read SEC document
May 02, 2023 Filed May 4, 2023 20:04 UTC	GeneDx Holdings Corp. WGS · Entity 1634	Exercise / conversionRestricted Stock Unit · Derivative	45,454	$0.00	$0.00	Disclosure SEC source: 0001209191-23-027315 · doc4.xml · derivative · entry 5 Casdin Eli · CIK 0001534264 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 45,454 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. F5 · derivative.exercise_date: The underlying shares shall vest on the earlier of the (a) date of the 2023 annual meeting of the Issuer's stockholders, and (b) first anniversary of the grant date, subject to the Reporting Person continuing to provide services to the Issuer on the applicable vesting date. F5 · derivative.expiration_date: The underlying shares shall vest on the earlier of the (a) date of the 2023 annual meeting of the Issuer's stockholders, and (b) first anniversary of the grant date, subject to the Reporting Person continuing to provide services to the Issuer on the applicable vesting date. Read SEC document
May 02, 2023 Filed May 4, 2023 20:04 UTC	GeneDx Holdings Corp. WGS · Entity 1634	Exercise / conversionClass A Common Stock	45,454	$0.00	$0.00	Disclosure SEC source: 0001209191-23-027315 · doc4.xml · nonDerivative · entry 1 Casdin Eli · CIK 0001534264 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,290 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
March 17, 2023 Filed Mar 22, 2023 10:02 UTC	SomaLogic, Inc. SLGC · Entity 95310	GrantEmployee Stock Option (right to buy) · Derivative	20,600	$0.00 Strike: $2.30	$0.00	Disclosure SEC source: 0001213900-23-021841 · ownership.xml · derivative · entry 2 Casdin Eli · CIK 0001534264 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,600 Underlying: Common Stock, par value $0.0001 · 20,600 shares Expires 2033-03-16 F1 · derivative.exercise_date: 100% of the shares underlying the option vest one year after the grant date, subject to the Reporting Person's continued service to the Issuer on each vesting date. Read SEC document
March 17, 2023 Filed Mar 22, 2023 10:02 UTC	SomaLogic, Inc. SLGC · Entity 95310	GrantCommon Stock	3,430	$0.00	$0.00	Disclosure SEC source: 0001213900-23-021841 · ownership.xml · nonDerivative · entry 1 Casdin Eli · CIK 0001534264 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,860 Read SEC document
January 31, 2023 Filed Feb 2, 2023 21:05 UTC	GeneDx Holdings Corp. WGS · Entity 1634	PurchaseClass A Common Stock	14,285,743	$0.35	$5,000,010.05	Disclosure SEC source: 0000899243-23-003400 · doc4.xml · nonDerivative · entry 2 Casdin Eli · CIK 0001534264 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Casdin Partners FO1-MSV, LP Disclosed balance after: 14,285,743 F2 · ownership.nature: The 14,285,743 shares of Class A common stock reported in the table above are owned directly by Casdin Partners FO1-MSV, LP and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to Casdin Partners FO1-MSV, LP, (ii) Casdin Partners GP, LLC, the general partner of Casdin Partners FO1-MSV, LP, and (iii) Mr. Casdin, the managing member of Casdin Capital, LLC and Casdin Partners GP, LLC. Each of Casdin Capital, LLC, Casdin Partners GP, LLC and Mr. Casdin disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein. Read SEC document
January 31, 2023 Filed Feb 2, 2023 21:05 UTC	GeneDx Holdings Corp. WGS · Entity 1634	PurchaseClass A Common Stock	71,428,542	$0.35	$24,999,989.70	Disclosure SEC source: 0000899243-23-003400 · doc4.xml · nonDerivative · entry 1 Casdin Eli · CIK 0001534264 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Casdin Partners Master Fund, LP Disclosed balance after: 87,866,042 F1 · ownership.nature: The 87,866,042 shares of Class A common stock reported in the table above are owned directly by Casdin Partners Master Fund, LP and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to Casdin Partners Master Fund, LP, (ii) Casdin Partners GP, LLC, the general partner of Casdin Partners Master Fund LP, and (iii) Mr. Casdin, the managing member of Casdin Capital, LLC and Casdin Partners GP, LLC. Each of Casdin Capital, LLC, Casdin Partners GP, LLC and Mr. Casdin disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein. Read SEC document
January 01, 2023 Filed Jan 4, 2023 21:55 UTC	EQRx, Inc. EQRX · Entity 108311	GrantEarn-out Shares · Derivative	3,959	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-23-001112 · tm231679-4_4seq1.xml · derivative · entry 3 Casdin Eli · CIK 0001534264 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Casdin Private Growth Equity Fund, L.P. Disclosed balance after: 755,766 Underlying: Common Stock · 3,959 shares Expires 2024-12-17 F1 · derivative.exercise_price: On January 1, 2023, the Reporting Person was allocated the right to acquire an additional 24,901 shares of the Issuer's Common Stock (the "Earn-out Shares"), (i) 17,430 of which will be released from escrow if the value weighted average price ("VWAP") for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $12.50; and (ii) 7,471 of which will be released from such escrow if the VWAP for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $16.50. Any Earn-out Shares not eligible to be released on or prior to December 17, 2024 will be forfeited and cancelled, and the maximum number of Earn-out Shares the Reporting Person may be eligible to acquire is subject to adjustment per the terms of the Agreement and Plan of Merger dated August 5, 2021 by and among the Issuer (f/k/a CM Life Sciences III Inc.), Clover III Merger Sub Inc. and EQRx International, Inc. (f/k/a EQRx, Inc.). F1 · kind: On January 1, 2023, the Reporting Person was allocated the right to acquire an additional 24,901 shares of the Issuer's Common Stock (the "Earn-out Shares"), (i) 17,430 of which will be released from escrow if the value weighted average price ("VWAP") for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $12.50; and (ii) 7,471 of which will be released from such escrow if the VWAP for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $16.50. Any Earn-out Shares not eligible to be released on or prior to December 17, 2024 will be forfeited and cancelled, and the maximum number of Earn-out Shares the Reporting Person may be eligible to acquire is subject to adjustment per the terms of the Agreement and Plan of Merger dated August 5, 2021 by and among the Issuer (f/k/a CM Life Sciences III Inc.), Clover III Merger Sub Inc. and EQRx International, Inc. (f/k/a EQRx, Inc.). F1 · price: On January 1, 2023, the Reporting Person was allocated the right to acquire an additional 24,901 shares of the Issuer's Common Stock (the "Earn-out Shares"), (i) 17,430 of which will be released from escrow if the value weighted average price ("VWAP") for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $12.50; and (ii) 7,471 of which will be released from such escrow if the VWAP for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $16.50. Any Earn-out Shares not eligible to be released on or prior to December 17, 2024 will be forfeited and cancelled, and the maximum number of Earn-out Shares the Reporting Person may be eligible to acquire is subject to adjustment per the terms of the Agreement and Plan of Merger dated August 5, 2021 by and among the Issuer (f/k/a CM Life Sciences III Inc.), Clover III Merger Sub Inc. and EQRx International, Inc. (f/k/a EQRx, Inc.). F1 · derivative.exercise_date: On January 1, 2023, the Reporting Person was allocated the right to acquire an additional 24,901 shares of the Issuer's Common Stock (the "Earn-out Shares"), (i) 17,430 of which will be released from escrow if the value weighted average price ("VWAP") for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $12.50; and (ii) 7,471 of which will be released from such escrow if the VWAP for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $16.50. Any Earn-out Shares not eligible to be released on or prior to December 17, 2024 will be forfeited and cancelled, and the maximum number of Earn-out Shares the Reporting Person may be eligible to acquire is subject to adjustment per the terms of the Agreement and Plan of Merger dated August 5, 2021 by and among the Issuer (f/k/a CM Life Sciences III Inc.), Clover III Merger Sub Inc. and EQRx International, Inc. (f/k/a EQRx, Inc.). F3 · ownership.direct: Casdin Capital, LLC is the investment advisor to CPMF, Casdin Venture Opportunities Fund, L.P. ("CVOF") and Casdin Private Growth Equity Fund, L.P. ("CPGEF"). Casdin Partners GP, LLC is the general partner of CPMF. Casdin Venture Opportunities Fund GP, LLC is the general partner of CVOF. Casdin Private Growth Equity Fund GP, LLC is the general partner of CPGEF. The Reporting Person is the managing member of Casdin Capital, LLC, Casdin Partners GP, LLC, Casdin Venture Opportunities Fund GP, LLC and Casdin Private Growth Equity Fund GP, LLC and may be deemed to have voting and investment power with respect to the shares. The Reporting Person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein, if any. F5 · ownership.direct: The shares are held directly by CPGEF. Read SEC document
January 01, 2023 Filed Jan 4, 2023 21:55 UTC	EQRx, Inc. EQRX · Entity 108311	GrantEarn-out Shares · Derivative	2,758	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-23-001112 · tm231679-4_4seq1.xml · derivative · entry 2 Casdin Eli · CIK 0001534264 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Casdin Venture Opportunities Fund, L.P. Disclosed balance after: 526,674 Underlying: Common Stock · 2,758 shares Expires 2024-12-17 F1 · derivative.exercise_price: On January 1, 2023, the Reporting Person was allocated the right to acquire an additional 24,901 shares of the Issuer's Common Stock (the "Earn-out Shares"), (i) 17,430 of which will be released from escrow if the value weighted average price ("VWAP") for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $12.50; and (ii) 7,471 of which will be released from such escrow if the VWAP for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $16.50. Any Earn-out Shares not eligible to be released on or prior to December 17, 2024 will be forfeited and cancelled, and the maximum number of Earn-out Shares the Reporting Person may be eligible to acquire is subject to adjustment per the terms of the Agreement and Plan of Merger dated August 5, 2021 by and among the Issuer (f/k/a CM Life Sciences III Inc.), Clover III Merger Sub Inc. and EQRx International, Inc. (f/k/a EQRx, Inc.). F1 · kind: On January 1, 2023, the Reporting Person was allocated the right to acquire an additional 24,901 shares of the Issuer's Common Stock (the "Earn-out Shares"), (i) 17,430 of which will be released from escrow if the value weighted average price ("VWAP") for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $12.50; and (ii) 7,471 of which will be released from such escrow if the VWAP for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $16.50. Any Earn-out Shares not eligible to be released on or prior to December 17, 2024 will be forfeited and cancelled, and the maximum number of Earn-out Shares the Reporting Person may be eligible to acquire is subject to adjustment per the terms of the Agreement and Plan of Merger dated August 5, 2021 by and among the Issuer (f/k/a CM Life Sciences III Inc.), Clover III Merger Sub Inc. and EQRx International, Inc. (f/k/a EQRx, Inc.). F1 · price: On January 1, 2023, the Reporting Person was allocated the right to acquire an additional 24,901 shares of the Issuer's Common Stock (the "Earn-out Shares"), (i) 17,430 of which will be released from escrow if the value weighted average price ("VWAP") for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $12.50; and (ii) 7,471 of which will be released from such escrow if the VWAP for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $16.50. Any Earn-out Shares not eligible to be released on or prior to December 17, 2024 will be forfeited and cancelled, and the maximum number of Earn-out Shares the Reporting Person may be eligible to acquire is subject to adjustment per the terms of the Agreement and Plan of Merger dated August 5, 2021 by and among the Issuer (f/k/a CM Life Sciences III Inc.), Clover III Merger Sub Inc. and EQRx International, Inc. (f/k/a EQRx, Inc.). F1 · derivative.exercise_date: On January 1, 2023, the Reporting Person was allocated the right to acquire an additional 24,901 shares of the Issuer's Common Stock (the "Earn-out Shares"), (i) 17,430 of which will be released from escrow if the value weighted average price ("VWAP") for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $12.50; and (ii) 7,471 of which will be released from such escrow if the VWAP for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $16.50. Any Earn-out Shares not eligible to be released on or prior to December 17, 2024 will be forfeited and cancelled, and the maximum number of Earn-out Shares the Reporting Person may be eligible to acquire is subject to adjustment per the terms of the Agreement and Plan of Merger dated August 5, 2021 by and among the Issuer (f/k/a CM Life Sciences III Inc.), Clover III Merger Sub Inc. and EQRx International, Inc. (f/k/a EQRx, Inc.). F3 · ownership.direct: Casdin Capital, LLC is the investment advisor to CPMF, Casdin Venture Opportunities Fund, L.P. ("CVOF") and Casdin Private Growth Equity Fund, L.P. ("CPGEF"). Casdin Partners GP, LLC is the general partner of CPMF. Casdin Venture Opportunities Fund GP, LLC is the general partner of CVOF. Casdin Private Growth Equity Fund GP, LLC is the general partner of CPGEF. The Reporting Person is the managing member of Casdin Capital, LLC, Casdin Partners GP, LLC, Casdin Venture Opportunities Fund GP, LLC and Casdin Private Growth Equity Fund GP, LLC and may be deemed to have voting and investment power with respect to the shares. The Reporting Person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein, if any. F4 · ownership.direct: The shares are held directly by CVOF. Read SEC document
January 01, 2023 Filed Jan 4, 2023 21:55 UTC	EQRx, Inc. EQRX · Entity 108311	GrantEarn-out Shares · Derivative	18,184	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-23-001112 · tm231679-4_4seq1.xml · derivative · entry 1 Casdin Eli · CIK 0001534264 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Casdin Partners Master Fund L.P. Disclosed balance after: 3,472,300 Underlying: Common Stock · 18,184 shares Expires 2024-12-17 F1 · derivative.exercise_price: On January 1, 2023, the Reporting Person was allocated the right to acquire an additional 24,901 shares of the Issuer's Common Stock (the "Earn-out Shares"), (i) 17,430 of which will be released from escrow if the value weighted average price ("VWAP") for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $12.50; and (ii) 7,471 of which will be released from such escrow if the VWAP for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $16.50. Any Earn-out Shares not eligible to be released on or prior to December 17, 2024 will be forfeited and cancelled, and the maximum number of Earn-out Shares the Reporting Person may be eligible to acquire is subject to adjustment per the terms of the Agreement and Plan of Merger dated August 5, 2021 by and among the Issuer (f/k/a CM Life Sciences III Inc.), Clover III Merger Sub Inc. and EQRx International, Inc. (f/k/a EQRx, Inc.). F1 · kind: On January 1, 2023, the Reporting Person was allocated the right to acquire an additional 24,901 shares of the Issuer's Common Stock (the "Earn-out Shares"), (i) 17,430 of which will be released from escrow if the value weighted average price ("VWAP") for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $12.50; and (ii) 7,471 of which will be released from such escrow if the VWAP for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $16.50. Any Earn-out Shares not eligible to be released on or prior to December 17, 2024 will be forfeited and cancelled, and the maximum number of Earn-out Shares the Reporting Person may be eligible to acquire is subject to adjustment per the terms of the Agreement and Plan of Merger dated August 5, 2021 by and among the Issuer (f/k/a CM Life Sciences III Inc.), Clover III Merger Sub Inc. and EQRx International, Inc. (f/k/a EQRx, Inc.). F1 · price: On January 1, 2023, the Reporting Person was allocated the right to acquire an additional 24,901 shares of the Issuer's Common Stock (the "Earn-out Shares"), (i) 17,430 of which will be released from escrow if the value weighted average price ("VWAP") for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $12.50; and (ii) 7,471 of which will be released from such escrow if the VWAP for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $16.50. Any Earn-out Shares not eligible to be released on or prior to December 17, 2024 will be forfeited and cancelled, and the maximum number of Earn-out Shares the Reporting Person may be eligible to acquire is subject to adjustment per the terms of the Agreement and Plan of Merger dated August 5, 2021 by and among the Issuer (f/k/a CM Life Sciences III Inc.), Clover III Merger Sub Inc. and EQRx International, Inc. (f/k/a EQRx, Inc.). F1 · derivative.exercise_date: On January 1, 2023, the Reporting Person was allocated the right to acquire an additional 24,901 shares of the Issuer's Common Stock (the "Earn-out Shares"), (i) 17,430 of which will be released from escrow if the value weighted average price ("VWAP") for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $12.50; and (ii) 7,471 of which will be released from such escrow if the VWAP for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $16.50. Any Earn-out Shares not eligible to be released on or prior to December 17, 2024 will be forfeited and cancelled, and the maximum number of Earn-out Shares the Reporting Person may be eligible to acquire is subject to adjustment per the terms of the Agreement and Plan of Merger dated August 5, 2021 by and among the Issuer (f/k/a CM Life Sciences III Inc.), Clover III Merger Sub Inc. and EQRx International, Inc. (f/k/a EQRx, Inc.). F2 · ownership.direct: The shares are held directly by Casdin Partners Master Fund L.P. ("CPMF"). F3 · ownership.direct: Casdin Capital, LLC is the investment advisor to CPMF, Casdin Venture Opportunities Fund, L.P. ("CVOF") and Casdin Private Growth Equity Fund, L.P. ("CPGEF"). Casdin Partners GP, LLC is the general partner of CPMF. Casdin Venture Opportunities Fund GP, LLC is the general partner of CVOF. Casdin Private Growth Equity Fund GP, LLC is the general partner of CPGEF. The Reporting Person is the managing member of Casdin Capital, LLC, Casdin Partners GP, LLC, Casdin Venture Opportunities Fund GP, LLC and Casdin Private Growth Equity Fund GP, LLC and may be deemed to have voting and investment power with respect to the shares. The Reporting Person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein, if any. Read SEC document
November 17, 2022 Filed Nov 26, 2022 00:05 UTC	Tenaya Therapeutics, Inc. TNYA · Entity 6506	PurchaseWarrant · Derivative	1,354,111	$2.60 Strike: $0.00	$3,519,334.49	Disclosure SEC source: 0000919574-22-006902 · ownership.xml · derivative · entry 2 Casdin Eli · CIK 0001534264 · Director Casdin Capital, LLC · CIK 0001534261 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,354,111 Underlying: Common Stock · 1,354,111 shares Expires not disclosed F2 · derivative.expiration_date: Each Warrant will be exercisable on or after the date of issuance until the date the Warrant is exercised in full. Each Warrant will be exercisable, in the holder's discretion, by (i) payment in full in immediately available funds for the number of shares of common stock purchased upon such exercise or (ii) a cashless exercise, in which case the holder would receive upon such exercise the net number of shares of common stock determined according to a pre-set formula. F1 · ownership.nature: The securities are owned directly by clients of Casdin Capital, LLC ("Casdin Capital") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, the investment adviser to such clients and (ii) Eli Casdin, the managing member of Casdin Capital. Read SEC document
November 17, 2022 Filed Nov 26, 2022 00:05 UTC	Tenaya Therapeutics, Inc. TNYA · Entity 6506	PurchaseCommon Stock	2,492,042	$2.60	$6,479,309.20	Disclosure SEC source: 0000919574-22-006902 · ownership.xml · nonDerivative · entry 1 Casdin Eli · CIK 0001534264 · Director Casdin Capital, LLC · CIK 0001534261 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 6,078,860 F1 · ownership.nature: The securities are owned directly by clients of Casdin Capital, LLC ("Casdin Capital") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, the investment adviser to such clients and (ii) Eli Casdin, the managing member of Casdin Capital. Read SEC document
October 03, 2022 Filed Oct 5, 2022 20:24 UTC	MAXCYTE, INC. MXCT · Entity 6608	SaleCommon Stock, par value $0.01 per share	735,786	$6.15	$4,525,083.90	Disclosure SEC source: 0000919574-22-005788 · ownership.xml · nonDerivative · entry 1 Casdin Partners Master Fund, L.P. · CIK 0001534265 · 10% owner Casdin Capital, LLC · CIK 0001534261 · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · 10% owner Casdin Eli · CIK 0001534264 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000,000 F1 · ownership.direct: (1) The securities are owned directly by Casdin Partners Master Fund, LP (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC, the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin Capital, LLC and Casdin Partners GP, LLC. Read SEC document
September 30, 2022 Filed Oct 4, 2022 20:24 UTC	EQRx, Inc. EQRX · Entity 108311	GrantStock Option (Right to Buy) · Derivative	101,010	$0.00 Strike: $4.95	$0.00	Disclosure SEC source: 0001104659-22-106014 · tm2227449-2_4seq1.xml · derivative · entry 1 Casdin Eli · CIK 0001534264 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,010 Underlying: Common Stock · 101,010 shares Expires 2032-09-30 F1 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable in full September 30, 2023, the one-year anniversary of the grant date, subject to the Reporting Person's continuous service on such vesting date, and subject to full acceleration upon the consummation of a Sale Event (as defined in the Issuer's 2021 Stock Option and Incentive Plan). Read SEC document
September 29, 2022 Filed Dec 14, 2022 22:40 UTC	SomaLogic, Inc. SLGC · Entity 95310	GrantClass A Common Stock	215,193	Not disclosed	Not disclosed	Disclosure SEC source: 0000919574-22-007074 · ownership.xml · nonDerivative · entry 1 Casdin Eli · CIK 0001534264 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 10,132,005 F1 · price: In connection with the closing (the "Closing") of the business combination (the "Business Combination") between the Issuer and Palamedrix, Inc., the selling shareholders collectively received (i) 4,030,472 shares of Common Stock and (ii) 5,578,388 shares of Common Stock which may be issuable upon the achievement of certain milestones. The forgoing description of the Business Combination does not purport to be complete and is subject to and qualified in its entirety by reference to the Issuer's S-3 filed on October 31, 2022, which is incorporated by reference. F2 · ownership.nature: The securities are owned directly by Casdin Partners Master Fund, LP (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC, the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin Capital, LLC and Casdin Partners GP, LLC. Read SEC document
July 01, 2022 Filed Jul 6, 2022 21:01 UTC	MAXCYTE, INC. MXCT · Entity 6608	SaleCommon Stock, par value $0.01 per share	3,235,548	$4.30	$13,912,856.40	Disclosure SEC source: 0000919574-22-004059 · ownership.xml · nonDerivative · entry 1 Casdin Partners Master Fund, L.P. · CIK 0001534265 · 10% owner Casdin Capital, LLC · CIK 0001534261 · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · 10% owner Casdin Eli · CIK 0001534264 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,735,786 F1 · ownership.direct: The securities are owned directly by Casdin Partners Master Fund, LP (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC, the general partner of the Master Fund, and (ii) Eli Casdin, the managing member of Casdin Capital, LLC and Casdin Partners GP, LLC. Read SEC document
June 15, 2022 Filed Jun 17, 2022 22:04 UTC	STANDARD BIOTOOLS INC. LAB · Entity 6116	GrantStock Option (Right to Buy) · Derivative	42,571	$1.86 Strike: $1.86	$79,182.06	Disclosure SEC source: 0001162194-22-000076 · wf-form4_165550347430647.xml · derivative · entry 2 Casdin Eli · CIK 0001534264 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,571 Underlying: Common Stock · 42,571 shares Expires 2032-06-15 F2 · derivative.exercise_date: The Option becomes exercisable in twelve equal monthly increments beginning on July 15, 2022. Read SEC document
June 15, 2022 Filed Jun 17, 2022 22:04 UTC	STANDARD BIOTOOLS INC. LAB · Entity 6116	GrantCommon Stock	30,914	$0.00	$0.00	Disclosure SEC source: 0001162194-22-000076 · wf-form4_165550347430647.xml · nonDerivative · entry 1 Casdin Eli · CIK 0001534264 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,766 F1 · shares: Represents Restricted Stock Units that vest in full on the earlier to occur of June 15, 2023 and one day prior to the date of the Issuer's next annual meeting of stockholders. Read SEC document
June 10, 2022 Filed Jun 14, 2022 00:45 UTC	Tenaya Therapeutics, Inc. TNYA · Entity 6506	GrantStock Option (Right to buy) · Derivative	39,727	$0.00 Strike: $5.26	$0.00	Disclosure SEC source: 0001209191-22-036521 · doc4.xml · derivative · entry 1 Casdin Eli · CIK 0001534264 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,727 Underlying: Common Stock · 39,727 shares Expires 2032-06-09 F1 · derivative.exercise_date: Option granted pursuant to the Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan. Option will vest in full upon the first anniversary of the date of grant or, if earlier, the day immediately before the date of the next annual meeting of stockholders that occurs after the grant date, subject to the Reporting Person continuing to be a service provider to the Issuer through each applicable vesting date. Read SEC document
June 09, 2022 Filed Jun 10, 2022 20:22 UTC	Century Therapeutics, Inc. IPSC · Entity 5739	GrantStock Option (right to buy) · Derivative	19,872	$0.00 Strike: $8.56	$0.00	Disclosure SEC source: 0001062993-22-014655 · form4.xml · derivative · entry 1 Casdin Eli · CIK 0001534264 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,872 Underlying: Common Stock · 19,872 shares Expires 2032-06-09 F1 · derivative.exercise_date: The option vests on the earlier of (a) June 9, 2023, or (b) the next annual meeting of stockholders, in each case subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document
June 08, 2022 Filed Jun 10, 2022 20:51 UTC	Absci Corp ABSI · Entity 4685	GrantStock Option (right to buy) · Derivative	28,700	$0.00 Strike: $3.39	$0.00	Disclosure SEC source: 0001628280-22-016853 · wf-form4_165489429483141.xml · derivative · entry 1 Casdin Eli · CIK 0001534264 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,700 Underlying: Common Stock · 28,700 shares Expires 2032-06-07 F1 · derivative.exercise_date: The shares subject to this option vest and become exercisable in full on the earlier of (i) the first anniversary of the date of grant and (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer through such date. Read SEC document
May 02, 2022 Filed May 5, 2022 00:24 UTC	GeneDx Holdings Corp. SMFR · Entity 1634	GrantRestricted Stock Unit · Derivative	45,454	$0.00	$0.00	Disclosure SEC source: 0001209191-22-027280 · doc4.xml · derivative · entry 2 Casdin Eli · CIK 0001534264 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,454 Underlying: Class A Common Stock · 45,454 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. F1 · derivative.exercise_date: The underlying shares shall vest the earlier of (a) the date of the next annual meeting of the Issuer's shareholders following the grant date, and (b) the first anniversary of the grant date, subject to the Reporting Person continuing to provide services to the Issuer through each vesting date. F1 · derivative.expiration_date: The underlying shares shall vest the earlier of (a) the date of the next annual meeting of the Issuer's shareholders following the grant date, and (b) the first anniversary of the grant date, subject to the Reporting Person continuing to provide services to the Issuer through each vesting date. Read SEC document
May 02, 2022 Filed May 5, 2022 00:24 UTC	GeneDx Holdings Corp. SMFR · Entity 1634	GrantStock Option (Right to Buy) · Derivative	78,914	$0.00 Strike: $2.16	$0.00	Disclosure SEC source: 0001209191-22-027280 · doc4.xml · derivative · entry 1 Casdin Eli · CIK 0001534264 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,914 Underlying: Class A Common Stock · 78,914 shares Expires 2032-05-01 F1 · derivative.exercise_date: The underlying shares shall vest the earlier of (a) the date of the next annual meeting of the Issuer's shareholders following the grant date, and (b) the first anniversary of the grant date, subject to the Reporting Person continuing to provide services to the Issuer through each vesting date. Read SEC document
May 02, 2022 Filed May 6, 2022 22:56 UTC Amendment	GeneDx Holdings Corp. SMFR · Entity 1634	GrantStock Option · Derivative	78,914	$0.00 Strike: $2.20	$0.00	Disclosure SEC source: 0001209191-22-027687 · doc4a.xml · derivative · entry 1 Casdin Eli · CIK 0001534264 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,914 Underlying: Class A Common Stock · 78,914 shares Expires 2032-05-01 F1 · derivative.exercise_price: This Form 4 amendment has been filed solely to correct the exercise price of a previously issued stock option to purchase shares of Class A Common Stock of the Issuer reported in a Form 4 filed on May 4, 2022 (the "Form 4"). The exercise price was inadvertently stated as $2.155 in the Form 4. The exercise price should have been stated as $2.20 in the Form 4. F2 · derivative.exercise_date: The underlying shares shall vest the earlier of (a) the date of the next annual meeting of the Issuer's shareholders following the grant date, and (b) the first anniversary of the grant date, subject to the Reporting Person continuing to provide services to the Issuer through each vesting date. Read SEC document
April 29, 2022 Filed May 3, 2022 20:01 UTC	GeneDx Holdings Corp. SMFR · Entity 1634	PurchaseClass A Common Stock	11,437,500	$4.00	$45,750,000.00	Disclosure SEC source: 0001213900-22-023579 · ownership.xml · nonDerivative · entry 1 Casdin Eli · CIK 0001534264 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Casdin Partners Master Fund, LP Disclosed balance after: 16,437,500 F1 · ownership.nature: The 11,437,500 shares of Class A common stock reported in the table above are owned directly by Casdin Partners Master Fund, LP and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to Casdin Partners Master Fund, LP, (ii) Casdin Partners GP, LLC, the general partner of Casdin Partners Master Fund LP, and (iii) Mr. Casdin, the managing member of Casdin Capital, LLC and Casdin Partners GP, LLC. Each of Casdin Capital, LLC, Casdin Partners GP, LLC and Mr. Casdin disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein. Read SEC document
April 27, 2022 Filed May 13, 2022 00:20 UTC	GeneDx Holdings Corp. SMFR · Entity 1634	Exercise / conversionRestricted Stock Unit · Derivative	12,836	$0.00	$0.00	Disclosure SEC source: 0001209191-22-028687 · doc4.xml · derivative · entry 2 Casdin Eli · CIK 0001534264 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 12,836 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. F2 · derivative.exercise_date: The RSUs will vest on the earlier of (i) the date of the next annual meeting of the Company's shareholders following the grant date and (i) the first anniversary of the grant date, in each case so long as the non-employee director continues to provide services to the Company through such vesting date. F2 · derivative.expiration_date: The RSUs will vest on the earlier of (i) the date of the next annual meeting of the Company's shareholders following the grant date and (i) the first anniversary of the grant date, in each case so long as the non-employee director continues to provide services to the Company through such vesting date. Read SEC document
April 27, 2022 Filed May 13, 2022 00:20 UTC	GeneDx Holdings Corp. SMFR · Entity 1634	Exercise / conversionClass A Common Stock	12,836	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-22-028687 · doc4.xml · nonDerivative · entry 1 Casdin Eli · CIK 0001534264 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,836 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. Read SEC document
April 04, 2022 Filed Apr 6, 2022 21:54 UTC	STANDARD BIOTOOLS INC. LAB · Entity 6116	GrantStock Option (Right to Buy) · Derivative	23,401	$0.00 Strike: $3.99	$0.00	Disclosure SEC source: 0000950142-22-001324 · es220241790_4-eclab.xml · derivative · entry 3 Casdin Eli · CIK 0001534264 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,401 Underlying: Common Stock · 23,401 shares Expires 2032-04-04 F5 · derivative.exercise_date: The Option becomes exercisable in four equal annual increments beginning on April 4, 2023. Read SEC document
April 04, 2022 Filed Apr 6, 2022 21:54 UTC	STANDARD BIOTOOLS INC. LAB · Entity 6116	GrantSeries B-1 Convertible Preferred Stock · Derivative	127,780	Not disclosed	Not disclosed	Disclosure SEC source: 0000950142-22-001324 · es220241790_4-eclab.xml · derivative · entry 2 Casdin Eli · CIK 0001534264 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 127,780 Underlying: Common Stock · 37,582,346 shares Expires not disclosed F2 · derivative.exercise_price: Each share of the Issuer's Series B-1 Convertible Preferred Stock (the "Series B-1 Preferred Stock") is convertible at the option of the Reporting Person at any time into a number of shares of the Issuer's common stock, par value $0.001 per share, equal to the conversion rate, which is initially 294.1176, subject to certain anti-dilution adjustments and limitations on conversion pursuant to the Certificate of Designation for the Series B-1 Preferred Stock. F3 · price: On April 4, 2022, the Issuer issued the Series B-1 Preferred Stock (i) in exchange for aggregate cash consideration of $112.5 million, pursuant to the Series B-1 Convertible Preferred Stock Purchase Agreement, dated as of January 23, 2022, among the Issuer, Casdin Partners Master Fund, L.P. ("Casdin Master Fund") and Casdin Private Growth Equity Fund II, L.P. ("Casdin Private Growth Fund") and (ii) upon the conversion of $12.5 million aggregate principal amount of term loans, including accrued and unpaid interest, pursuant to the Series B-1 Loan Agreement, dated as of January 23, 2022, among the Issuer, Casdin Master Fund and Casdin Private Growth Fund. F2 · derivative.exercise_date: Each share of the Issuer's Series B-1 Convertible Preferred Stock (the "Series B-1 Preferred Stock") is convertible at the option of the Reporting Person at any time into a number of shares of the Issuer's common stock, par value $0.001 per share, equal to the conversion rate, which is initially 294.1176, subject to certain anti-dilution adjustments and limitations on conversion pursuant to the Certificate of Designation for the Series B-1 Preferred Stock. F2 · derivative.expiration_date: Each share of the Issuer's Series B-1 Convertible Preferred Stock (the "Series B-1 Preferred Stock") is convertible at the option of the Reporting Person at any time into a number of shares of the Issuer's common stock, par value $0.001 per share, equal to the conversion rate, which is initially 294.1176, subject to certain anti-dilution adjustments and limitations on conversion pursuant to the Certificate of Designation for the Series B-1 Preferred Stock. F2 · derivative.underlying_shares: Each share of the Issuer's Series B-1 Convertible Preferred Stock (the "Series B-1 Preferred Stock") is convertible at the option of the Reporting Person at any time into a number of shares of the Issuer's common stock, par value $0.001 per share, equal to the conversion rate, which is initially 294.1176, subject to certain anti-dilution adjustments and limitations on conversion pursuant to the Certificate of Designation for the Series B-1 Preferred Stock. F4 · ownership.nature: These shares are held by Casdin Master Fund and Casdin Private Growth Fund. Casdin Capital, LLC ("Casdin Capital") is the investment adviser to Casdin Master Fund and Casdin Private Growth Fund. Casdin Partners GP, LLC ("Casdin Partners GP") is the general partner of Casdin Master Fund and Casdin Private Growth Equity Fund II GP, LLC ("Casdin Private Growth GP") is the general partner of Casdin Private Growth Fund. Eli Casdin is the managing member of Casdin Capital, Casdin Partners GP and Casdin Private Growth GP. Each of Casdin Capital, Casdin Partners GP, Casdin Private Growth GP and Eli Casdin disclaims beneficial ownership of such securities except to the extent of their respective pecuniary interest therein, if any. Read SEC document
April 04, 2022 Filed Apr 6, 2022 21:54 UTC	STANDARD BIOTOOLS INC. LAB · Entity 6116	GrantCommon Stock	15,852	$0.00	$0.00	Disclosure SEC source: 0000950142-22-001324 · es220241790_4-eclab.xml · nonDerivative · entry 1 Casdin Eli · CIK 0001534264 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,852 F1 · shares: Represents Restricted Stock Units that vest in four equal annual increments beginning April 4, 2023. Read SEC document
March 01, 2022 Filed Mar 4, 2022 02:08 UTC	SomaLogic, Inc. SLGC · Entity 95310	GrantEmployee Stock Option (right to buy) · Derivative	20,600	$0.00 Strike: $9.08	$0.00	Disclosure SEC source: 0001062993-22-006752 · form4.xml · derivative · entry 2 Casdin Eli · CIK 0001534264 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,600 Underlying: Common Stock, par value $0.0001 · 20,600 shares Expires 2032-02-29 F1 · derivative.exercise_date: 100% of the shares underlying the option vest one year after the grant date, subject to the Reporting Person's continued service to the Issuer on each vesting date. Read SEC document
March 01, 2022 Filed Mar 4, 2022 02:08 UTC	SomaLogic, Inc. SLGC · Entity 95310	GrantCommon Stock	3,430	$0.00	$0.00	Disclosure SEC source: 0001062993-22-006752 · form4.xml · nonDerivative · entry 1 Casdin Eli · CIK 0001534264 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,430 Read SEC document
December 17, 2021 Filed Dec 21, 2021 17:20 UTC	EQRx, Inc. EQRX · Entity 108311	GrantWarrants to purchase Class A Common Stock (right to buy) · Derivative	8,110,001	Not disclosed Strike: $11.50	Not disclosed	Disclosure SEC source: 0001213900-21-066755 · ownership.xml · derivative · entry 6 Casdin Eli · CIK 0001534264 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By CMLS Holdings III LLC Disclosed balance after: 8,110,001 Underlying: Common Stock · 8,110,001 shares Expires 2026-12-17 F4 · kind: Following the completion of the Business Combination, warrants to purchase Class A Common Stock become exercisable on April 9, 2022. F4 · price: Following the completion of the Business Combination, warrants to purchase Class A Common Stock become exercisable on April 9, 2022. F2 · ownership.nature: The securities are held of record by CMLS Holdings III LLC ("CMLS Holdings III"). CMLS Holdings III is the record holder of the Class A common stock and the Class A Common Stock issuable upon the exercise of warrants reported herein. Mr. Casdin is a member of the Board of Managers of CMLS Holdings III and as a result shares voting and investment discretion with respect to the Class A common stock held of record by CMLS Holdings III. Mr. Casdin disclaims beneficial ownership of these shares except to the extent of his respective pecuniary interest therein. Read SEC document
December 17, 2021 Filed Dec 21, 2021 17:20 UTC	EQRx, Inc. EQRX · Entity 108311	OtherClass B Common Stock · Derivative	8,659,372	$0.00	$0.00	Disclosure SEC source: 0001213900-21-066755 · ownership.xml · derivative · entry 5 Casdin Eli · CIK 0001534264 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By CMLS Holdings III LLC Disclosed balance after: 0 Underlying: Common Stock · 8,659,372 shares Expires not disclosed F1 · derivative.exercise_price: In connection with the closing (the "Closing") of the business combination (the "Business Combination") between the Issuer (which was formerly known as CM Life Sciences III Inc. or "CMLS III") and EQRx, Inc. ("EQRx"), among other things, (i) the Reporting Person forfeited 4,840,628 shares of CMLS III Class B common stock and (ii) each remaining share of CMLS III's Class B common stock converted pursuant to the terms of such stock into shares of the Issuer's Class A Common Stock on a one-for-one basis as described under the heading "Description of Securities" in the Issuer's Registration Statement on Form S-1 (File No. 333-253475). F1 · kind: In connection with the closing (the "Closing") of the business combination (the "Business Combination") between the Issuer (which was formerly known as CM Life Sciences III Inc. or "CMLS III") and EQRx, Inc. ("EQRx"), among other things, (i) the Reporting Person forfeited 4,840,628 shares of CMLS III Class B common stock and (ii) each remaining share of CMLS III's Class B common stock converted pursuant to the terms of such stock into shares of the Issuer's Class A Common Stock on a one-for-one basis as described under the heading "Description of Securities" in the Issuer's Registration Statement on Form S-1 (File No. 333-253475). F1 · derivative.exercise_date: In connection with the closing (the "Closing") of the business combination (the "Business Combination") between the Issuer (which was formerly known as CM Life Sciences III Inc. or "CMLS III") and EQRx, Inc. ("EQRx"), among other things, (i) the Reporting Person forfeited 4,840,628 shares of CMLS III Class B common stock and (ii) each remaining share of CMLS III's Class B common stock converted pursuant to the terms of such stock into shares of the Issuer's Class A Common Stock on a one-for-one basis as described under the heading "Description of Securities" in the Issuer's Registration Statement on Form S-1 (File No. 333-253475). F1 · derivative.expiration_date: In connection with the closing (the "Closing") of the business combination (the "Business Combination") between the Issuer (which was formerly known as CM Life Sciences III Inc. or "CMLS III") and EQRx, Inc. ("EQRx"), among other things, (i) the Reporting Person forfeited 4,840,628 shares of CMLS III Class B common stock and (ii) each remaining share of CMLS III's Class B common stock converted pursuant to the terms of such stock into shares of the Issuer's Class A Common Stock on a one-for-one basis as described under the heading "Description of Securities" in the Issuer's Registration Statement on Form S-1 (File No. 333-253475). F2 · ownership.nature: The securities are held of record by CMLS Holdings III LLC ("CMLS Holdings III"). CMLS Holdings III is the record holder of the Class A common stock and the Class A Common Stock issuable upon the exercise of warrants reported herein. Mr. Casdin is a member of the Board of Managers of CMLS Holdings III and as a result shares voting and investment discretion with respect to the Class A common stock held of record by CMLS Holdings III. Mr. Casdin disclaims beneficial ownership of these shares except to the extent of his respective pecuniary interest therein. Read SEC document
December 17, 2021 Filed Dec 21, 2021 17:20 UTC	EQRx, Inc. EQRX · Entity 108311	OtherClass B Common Stock · Derivative	4,840,628	$0.00	$0.00	Disclosure SEC source: 0001213900-21-066755 · ownership.xml · derivative · entry 4 Casdin Eli · CIK 0001534264 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By CMLS Holdings III LLC Disclosed balance after: 0 Underlying: Common Stock · 4,840,628 shares Expires not disclosed F1 · derivative.exercise_price: In connection with the closing (the "Closing") of the business combination (the "Business Combination") between the Issuer (which was formerly known as CM Life Sciences III Inc. or "CMLS III") and EQRx, Inc. ("EQRx"), among other things, (i) the Reporting Person forfeited 4,840,628 shares of CMLS III Class B common stock and (ii) each remaining share of CMLS III's Class B common stock converted pursuant to the terms of such stock into shares of the Issuer's Class A Common Stock on a one-for-one basis as described under the heading "Description of Securities" in the Issuer's Registration Statement on Form S-1 (File No. 333-253475). F1 · kind: In connection with the closing (the "Closing") of the business combination (the "Business Combination") between the Issuer (which was formerly known as CM Life Sciences III Inc. or "CMLS III") and EQRx, Inc. ("EQRx"), among other things, (i) the Reporting Person forfeited 4,840,628 shares of CMLS III Class B common stock and (ii) each remaining share of CMLS III's Class B common stock converted pursuant to the terms of such stock into shares of the Issuer's Class A Common Stock on a one-for-one basis as described under the heading "Description of Securities" in the Issuer's Registration Statement on Form S-1 (File No. 333-253475). F1 · derivative.exercise_date: In connection with the closing (the "Closing") of the business combination (the "Business Combination") between the Issuer (which was formerly known as CM Life Sciences III Inc. or "CMLS III") and EQRx, Inc. ("EQRx"), among other things, (i) the Reporting Person forfeited 4,840,628 shares of CMLS III Class B common stock and (ii) each remaining share of CMLS III's Class B common stock converted pursuant to the terms of such stock into shares of the Issuer's Class A Common Stock on a one-for-one basis as described under the heading "Description of Securities" in the Issuer's Registration Statement on Form S-1 (File No. 333-253475). F1 · derivative.expiration_date: In connection with the closing (the "Closing") of the business combination (the "Business Combination") between the Issuer (which was formerly known as CM Life Sciences III Inc. or "CMLS III") and EQRx, Inc. ("EQRx"), among other things, (i) the Reporting Person forfeited 4,840,628 shares of CMLS III Class B common stock and (ii) each remaining share of CMLS III's Class B common stock converted pursuant to the terms of such stock into shares of the Issuer's Class A Common Stock on a one-for-one basis as described under the heading "Description of Securities" in the Issuer's Registration Statement on Form S-1 (File No. 333-253475). F2 · ownership.nature: The securities are held of record by CMLS Holdings III LLC ("CMLS Holdings III"). CMLS Holdings III is the record holder of the Class A common stock and the Class A Common Stock issuable upon the exercise of warrants reported herein. Mr. Casdin is a member of the Board of Managers of CMLS Holdings III and as a result shares voting and investment discretion with respect to the Class A common stock held of record by CMLS Holdings III. Mr. Casdin disclaims beneficial ownership of these shares except to the extent of his respective pecuniary interest therein. Read SEC document
December 17, 2021 Filed Dec 21, 2021 17:20 UTC	EQRx, Inc. EQRX · Entity 108311	GrantCommon Stock	5,000,000	$10.00	$50,000,000.00	Disclosure SEC source: 0001213900-21-066755 · ownership.xml · nonDerivative · entry 3 Casdin Eli · CIK 0001534264 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Casdin Partners Master Fund, L.P. Disclosed balance after: 48,187,043 F3 · ownership.nature: The securities may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to Casdin Partners Master Fund, L.P. ("CPMF"), (Casdin Venture Opportunities Fund, L.P. ("CVOF") and Casdin Private Growth Equity Fund GP, LLC. ("CPGEF" and together with CPMF and CVOF, the "Casdin Funds") (ii) Casdin Partners GP, LLC, the general partner of CPMF, (iii) Casdin Venture Opportunities Fund GP, LLC, the general partner to CVOF, (iv) Casdin Private Growth Equity Funds GP, LLC, the general partner of CPGEF and (v) Eli Casdin, the managing member of Casdin Capital, LLC and Casdin Partners GP, LLC. The shares held by Casdin Partners GP, LLC may be deemed to be indirectly beneficially owned by (i) Eli Casdin, the managing member of Casdin Partners GP, LLC. The address for the Casdin entities noted herein is 1350 Avenue of the Americas, Suite 2600, New York, New York 10019. Mr. Casdin disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein.) Read SEC document
December 17, 2021 Filed Dec 21, 2021 17:20 UTC	EQRx, Inc. EQRX · Entity 108311	GrantCommon Stock	34,527,671	$0.00	$0.00	Disclosure SEC source: 0001213900-21-066755 · ownership.xml · nonDerivative · entry 2 Casdin Eli · CIK 0001534264 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Casdin Partners Master Fund, L.P. Disclosed balance after: 43,187,043 F3 · ownership.nature: The securities may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to Casdin Partners Master Fund, L.P. ("CPMF"), (Casdin Venture Opportunities Fund, L.P. ("CVOF") and Casdin Private Growth Equity Fund GP, LLC. ("CPGEF" and together with CPMF and CVOF, the "Casdin Funds") (ii) Casdin Partners GP, LLC, the general partner of CPMF, (iii) Casdin Venture Opportunities Fund GP, LLC, the general partner to CVOF, (iv) Casdin Private Growth Equity Funds GP, LLC, the general partner of CPGEF and (v) Eli Casdin, the managing member of Casdin Capital, LLC and Casdin Partners GP, LLC. The shares held by Casdin Partners GP, LLC may be deemed to be indirectly beneficially owned by (i) Eli Casdin, the managing member of Casdin Partners GP, LLC. The address for the Casdin entities noted herein is 1350 Avenue of the Americas, Suite 2600, New York, New York 10019. Mr. Casdin disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein.) Read SEC document
December 17, 2021 Filed Dec 21, 2021 17:20 UTC	EQRx, Inc. EQRX · Entity 108311	OtherCommon Stock	8,659,372	$0.00	$0.00	Disclosure SEC source: 0001213900-21-066755 · ownership.xml · nonDerivative · entry 1 Casdin Eli · CIK 0001534264 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By CMLS Holdings III LLC Disclosed balance after: 8,659,372 F1 · kind: In connection with the closing (the "Closing") of the business combination (the "Business Combination") between the Issuer (which was formerly known as CM Life Sciences III Inc. or "CMLS III") and EQRx, Inc. ("EQRx"), among other things, (i) the Reporting Person forfeited 4,840,628 shares of CMLS III Class B common stock and (ii) each remaining share of CMLS III's Class B common stock converted pursuant to the terms of such stock into shares of the Issuer's Class A Common Stock on a one-for-one basis as described under the heading "Description of Securities" in the Issuer's Registration Statement on Form S-1 (File No. 333-253475). F2 · ownership.nature: The securities are held of record by CMLS Holdings III LLC ("CMLS Holdings III"). CMLS Holdings III is the record holder of the Class A common stock and the Class A Common Stock issuable upon the exercise of warrants reported herein. Mr. Casdin is a member of the Board of Managers of CMLS Holdings III and as a result shares voting and investment discretion with respect to the Class A common stock held of record by CMLS Holdings III. Mr. Casdin disclaims beneficial ownership of these shares except to the extent of his respective pecuniary interest therein. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.